

MECHANISMS OF VASCULAR DISEASE:

A REFERENCE BOOK FOR VASCULAR SPECIALISTS



EDITED BY ROBERT FITRIDGE AND MATTHEW THOMPSON
COMPLETELY UPDATED EDITION 2011

BARR SMITH PRESS

Mechanisms of Vascular Disease

Mechanisms of Vascular Disease:

A Reference Book for Vascular Specialists

Robert Fitridge

The University of Adelaide, The Queen Elizabeth Hospital, Woodville, Australia

Matthew Thompson

St George's Hospital Medical School, London, UK



BARR SMITH PRESS

An imprint of
The University of Adelaide Press

Published in Adelaide by

The University of Adelaide, Barr Smith Press
Barr Smith Library
The University of Adelaide
South Australia 5005
press@adelaide.edu.au
www.adelaide.edu.au/press

The University of Adelaide Press publishes peer-reviewed scholarly works by staff via Open Access online editions and print editions.

The Barr Smith Press is an imprint of the University of Adelaide Press, reserved for scholarly works which are not available in Open Access, as well as titles of interest to the University and its associates. The Barr Smith Press logo features a woodcut of the original Barr Smith Library entrance.

© The Contributors 2011

This book is copyright. Apart from any fair dealing for the purposes of private study, research, criticism or review as permitted under the Copyright Act, no part may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission. Address all inquiries to the Director at the above address.

This CIP cataloguing for this work is as follows;

Mechanisms of vascular disease : a reference book for vascular surgeons / Robert Fitridge, Matthew Thompson, [editors].

1. Blood vessels, Diseases.
2. Blood vessels, Surgery.

- I. Fitridge, Robert
- II. Thompson, M. M.

For the full Cataloguing-in-Publication data please contact National Library of Australia:
cip@nla.gov.au

ISBN (paperback) 978-0-9871718-2-5

Book design: Midland Typesetters

Cover design: Emma Spoehr, based on a diagram by Dave Heinrich of the Medical Illustration and Media Unit, Flinders Medical Centre

Paperback edition printed by Griffin Press, South Australia

Table of Contents

Contributors vii

Detailed Contents xi

1. Endothelium 1
Paul Kerr, Raymond Tam, Frances Plane (Calgary, Canada)
2. Vascular smooth muscle structure and function 13
David Wilson (Adelaide, Australia)
3. Atherosclerosis 25
Gillian Cockerill, Qingbo Xu (London, UK)
4. Mechanisms of plaque rupture 43
Ian Loftus (London, UK)
5. Current and emerging therapies in atheroprotection 79
Stephen Nicholls, Rishi Puri (Cleveland, USA)
6. Molecular approaches to revascularisation in peripheral vascular disease 103
Greg McMahon, Mark McCarthy (Leicester, UK)
7. Biology of restenosis and targets for intervention 115
Richard Kenagy (Seattle, USA)
8. Vascular arterial haemodynamics 153
Michael Lawrence-Brown, Kurt Liffman, James Semmens, Ilija Sutalo (Melbourne & Perth, Australia)
9. Physiological haemostasis 177
Simon McRae (Adelaide, Australia)
10. Hypercoagulable states 189
Simon McRae (Adelaide, Australia)
11. Platelets in the pathogenesis of vascular disease and their role as a therapeutic target 201
Sandeep Prabhu, Rahul Sharma, Karlheinz Peter (Melbourne, Australia)
12. Pathogenesis of aortic aneurysms 227
Jonathan Golledge, Guo-Ping Shi, Paul Norman (Townsville & Perth, Australia; Boston, USA)
13. Pharmacological treatment of aneurysms 247
Matthew Thompson, Janet Powell (London, UK)
14. Aortic dissection and connective tissue disorders 255
Mark Hamilton (Adelaide, Australia)
15. Biomarkers in vascular disease 277
Ian Nordon, Robert Hincliffe (London, UK)
16. Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon 295
Martin Veller (Johannesburg, South Africa)
17. SIRS, sepsis and multiorgan failure 315
Vishwanath Biradar, John Moran (Adelaide, Australia)
18. Pathophysiology of reperfusion injury 331
Prue Cowled, Robert Fitridge (Adelaide, Australia)
19. Compartment syndrome 351
Edward Choke, Robert Sayers, Matthew Bown (Leicester, UK)
20. Pathophysiology of pain 375
Stephan Schug, Helen Daly, Kathryn Stannard (Perth, Australia)

21. Postamputation pain 389
Stephan Schug, Gail Gillespie
(Perth, Australia)
 22. Treatment of neuropathic pain 401
Stephan Schug, Kathryn Stannard
(Perth, Australia)
 23. Principles of wound healing 423
Gregory Schultz, Gloria Chin,
Lyle Moldauer, Robert Diegelmann
(Florida, USA)
 24. Pathophysiology and principles of
varicose veins 451
Andrew Bradbury (Birmingham, UK)
 25. Chronic venous insufficiency and leg
ulceration: Principles and vascular
biology 459
Michael Stacey (Perth, Australia)
 26. Pathophysiology and principles of
management of the diabetic foot 475
David Armstrong, Timothy Fisher,
Brian Lepow, Matthew White,
Joseph Mills (Tucson, USA)
 27. Lymphoedema – Principles, genetics
and pathophysiology 497
Matt Waltham (London, UK)
 28. Graft materials past and future 511
Mital Desai, George Hamilton
(London, UK)
 29. Pathophysiology of vascular graft
infections 537
Mauro Vicaretti (Sydney, Australia)
- Index 549

List of Contributors

David G Armstrong
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Vishwanath Biradar
Intensive Care Unit
The Queen Elizabeth Hospital
Woodville, SA
Australia

Matthew Bown
Department of Vascular Surgery
University of Leicester
Leicester
UK

Andrew W Bradbury
University Department of Vascular Surgery
Birmingham Heartlands Hospital
Birmingham
UK

Edward Choke
Department of Vascular Surgery
University of Leicester
Leicester
UK

Gillian Cockerill
Department of Clinical Sciences
St George's Hospital Medical School
London
UK

Prue Cowled
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Helen Daly
Royal Perth Hospital
Perth, WA
Australia

Mital Desai
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Robert F Diegelmann
Department of Biochemistry
Medical College of Virginia
Richmond, VA
USA

Timothy K Fisher
Rashid Centre for Diabetes and Research
Sheikh Khalifa Hospital
Ajmon
UAE

Robert A Fitridge
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Gail Gillespie
Royal Perth Hospital
Perth, WA
Australia

Jonathan Golledge
Vascular Biology Unit
School of Medicine & Dentistry
James Cook University
Townsville, QLD
Australia

George Hamilton
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Mark Hamilton
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Robert J Hinchliffe
St George's Vascular Institute
St George's Hospital
London
UK

Richard D Kenagy
Department of Surgery
University of Washington
Seattle, WA
USA

Paul Kerr
Department of Pharmacology
University of Alberta
Alberta
Canada

Michael MD Lawrence-Brown
Curtin Health Innovation Research
Institute
Curtin University
Perth, WA
Australia

Brian Lepow
The University of Arizona
Department of Surgery
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Kurt Liffman
CSIRO Material Science & Engineering
and School of Mathematical Sciences
Monash University
Melbourne, Vic
Australia

Ian Loftus
Department of Vascular Surgery
St George's Hospital
London
UK

Mark J McCarthy
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Greg S McMahon
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Simon McRae
Adult Haemophilia Treatment Centre
SA Pathology
Adelaide, SA
Australia

Joseph L Mills
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Lyle Moldawer
Department of Surgery
University of Florida
Gainesville, FL
USA

John L Moran
Faculty of Health Sciences
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Stephen Nicholls
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Ian M Nordon
St George's Vascular Institute
St George's Hospital
London
UK

Paul E Norman
School of Surgery
University of WA
Fremantle, WA
Australia

Karlheinz Peter
Baker IDI Heart & Diabetes Institute
Melbourne, Vic
Australia

Frances Plane
Department of Pharmacology
University of Alberta
Alberta
Canada

Janet T Powell
Imperial College
London
UK

Sandeep Prabhu
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Rishi Puri
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Stephan A Schug
Royal Perth Hospital
Perth, WA
Australia

Gregory S Schultz
Department of Obstetrics and Gynaecology
University of Florida
Gainesville, FL
USA

Rahul Sharma
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Guo-Ping Shi
Department of Cardiovascular Medicine
Brigham & Women's Hospital
Harvard Medical School
Boston, MA
USA

Michael Stacey
University Department of Surgery
Fremantle Hospital
Fremantle, WA
Australia

Ilija D Sutalo
CSIRO Material Science & Engineering
and Curtin Health Innovation
Research Institute
Curtin University
Highett, Vic

Raymond Tam
Department of Pharmacology
University of Alberta
Alberta
Canada

Matthew Thompson
St Georges Hospital Medical School
London
UK

Martin Veller
Department of Surgery
University of Witwatersrand
Johannesburg
South Africa

Mauro Vicaretti
Department of Vascular Surgery
Westmead Hospital
Westmead, NSW
Australia

Matt Waltham
Academic Department of Surgery
St Thomas' Hospital
London
UK

Matthew L White
Vascular and Endovascular Surgery
University of Arizona
Tucson, AZ
USA

David P Wilson
School of Medical Sciences
Discipline of Physiology
University of Adelaide
Adelaide SA
Australia

Qingbo Xu
Department of Cardiology
Kings College
University of London
UK

Detailed Contents

CHAPTER 1 – ENDOTHELIUM

Paul Kerr, Raymond Tam, Frances Plane

- Introduction 1
- Endothelium-dependent regulation of vascular tone 2
- Angiogenesis 7
- Haemostasis 8
- Inflammation 9
- Conclusions 10
- References

CHAPTER 2 – VASCULAR SMOOTH MUSCLE STRUCTURE AND FUNCTION

David Wilson

- Introduction 13
- Smooth muscle (vascular) structure
- Cytoskeleton 14
- Contractile myofilament
- Functional regulation of vascular smooth muscle: Neuronal, hormonal, receptor mediated 15
- Smooth muscle function 17
- Myofilament basis of smooth muscle contraction and relaxation
- Smooth muscle contraction and relaxation 18
- Ion channels important in the regulation of smooth muscle function
- Regulation of cellular Ca^{2+}
- Sources of cytosolic Ca^{2+} entry 19
- Potassium channels
- Endothelial regulation of smooth muscle vasodilatation 20

Smooth muscle proliferation and vascular remodeling 20

Summary 22

References

CHAPTER 3 – ATHEROSCLEROSIS

Gillian Cockerill, Qingbo Xu

Introduction 25

Atherosclerotic lesions 26

Fatty streaks

Plaque or atheroma

Hypercholesterolemia and oxidised-LDL 27

High-density lipoproteins role in atheroprotection 28

Hypertension and biomechanical stress 29

Biomechanical stress-induced cell death 30

Biomechanical stress and inflammation 31

Biomechanical stress-induced smooth muscle cell proliferation 32

Infections and heat shock proteins

Infections

Heat shock proteins 33

Infections and HSP expression

Infections, sHSP and innate immunity 34

Immune responses 36

MHC class II antigens and T cells

Oxidised LDL as a candidate antigen

HSP60 as a candidate antigen 37

B2-glycoprotein Ib as a candidate antigen

Inflammation

C-reactive protein	38
CD40/CD40L	
Summary and perspectives	39
References	

CHAPTER 4 – MECHANISMS OF PLAQUE RUPTURE

Ian Loftus

Introduction	43
Evidence for the ‘plaque rupture theory’	44
Coronary circulation	
Cerebral circulation	
The role of individual components of the arterial wall	
The endothelium	45
The lipid core	47
The cap of the plaque	49
Smooth muscle cells and collagen production	50
Macrophages and collagen degradation	51
The vessel lumen	56
The role of angiogenesis in plaque rupture	
The role of infectious agents in plaque rupture	57
Risk prediction of plaque instability	58
Imaging	
Blood markers	59
Therapy aimed at plaque stabilisation	
HMG Co-A reductase inhibitors	60
MMP inhibition	
Tissue inhibitors of metalloproteinases (TIMPs)	61
Synthetic MMP inhibitors	
Doxycycline	
ACE inhibitors	
Summary	62
References	63

CHAPTER 5 – CURRENT AND EMERGING THERAPIES IN ATHEROPROTECTION

Stephen Nicholls, Rishi Puri

Background	79
Pathology	
Risk factor modification	80
Statins, LDL lowering and C-reactive protein	
The complexity of HDL	84
The controversy of triglycerides	87
Hypertension	
Risk factor modification in the diabetic patient	89
Glycaemic control	
Global risk factor reduction in diabetics	91
The metabolic syndrome	92
Future targets	93
Conclusion	
References	94

CHAPTER 6 – MOLECULAR APPROACHES TO REVASCULARISATION IN PERIPHERAL VASCULAR DISEASE

Greg S McMahon, Mark J McCarthy

Introduction	103
Mechanisms of vascular growth	
Vasculogenesis	
Angiogenesis	104
Neovessel maturation	105
Microvascular network maturation	106
Arteriogenesis	
Therapeutic induction of vascular growth	107
Delivery of molecular activators of vascular growth	
Angiogenic activators	108
Arteriogenic activators	109
Clinical trials for angiogenic therapy of peripheral vascular disease	
Conclusions	110
References	

CHAPTER 7 – BIOLOGY OF RESTENOSIS AND TARGETS FOR INTERVENTION

Richard Kenagy

Introduction 115

Mechanisms of restenosis

Thrombosis 116

Remodelling

Intimal hyperplasia 123

Sequence of events after injury

Origin of intimal cells 125

Inflammation 126

Role of ECM production 127

The contribution of specific factors to restenosis

Growth factors/cytokines

Inhibitors 128

Coagulation and fibrinolytic factors 129

Matrix metalloproteinases

Extracellular matrix/receptors

Targets for intervention 130

Intracellular signalling molecules

mTOR and microtubules

Transcription factors

miRNA 131

Inflammation targets

Brachytherapy

Extracellular targets and cell-based therapies

Angiotensin pathway

Cell-based therapies 132

Differential effects on endothelium and SMCs

Delivery devices

Prevention versus reversal of restenosis

Conclusions 133

References 134

CHAPTER 8 – VASCULAR ARTERIAL HAEMODYNAMICS

Michael Lawrence Brown, Kurt Liffman, James Semmens, Ilija Sutalo

Introduction 153

Laplace's law of wall of tension 154

Newtonian fluid 155

Non-Newtonian fluid

Poiseuille flow 158

Bernoulli's equation

Young's modulus and pulsatile flow 159

Mass conversion 161

Reynold's number

Arterial dissection, collateral circulation and competing flows 163

Shear stress and pressure 164

Forces on graft systems 165

Case 1 – The cylindrical graft 168

Case 2 – The windsock graft

Case 3 – The curved graft 169

Case 4 – The symmetric bifurcated graft

Computational modelling 170

Recent development and future directions 171

Conclusions 172

References 173

CHAPTER 9 – PHYSIOLOGICAL HAEMOSTASIS

Simon McRae

Introduction 177

Primary haemostasis

Platelets

Platelet adhesion

Platelet activation and shape change 179

Platelet aggregation 180

Interactions between primary and secondary haemostasis 181

Secondary haemostasis

The coagulation cascade 182

Initiation 183

Amplification

Propagation 184

Normal inhibitors of coagulation

Fibrinolysis 185

Conclusions 186

References

CHAPTER 10 – HYPERCOAGULABLE STATES

Simon McRae

Introduction 189

Classification of thrombophilia

Inherited thrombophilia 190

Type 1 conditions

Antithrombin deficiency

Protein C and Protein S deficiency

Type 2 conditions 191

Factor V Leiden

The prothrombin (G20210A) gene mutation

FVL/PGM compound heterozygotes

Other inherited conditions

Acquired thrombophilia 192

Antiphospholipid antibodies

Heparin induced thrombocytopenia

Myeloproliferative disorders 193

Potential reasons for performing thrombophilia testing

Patients with venous thrombosis and their relatives

Providing an understanding of the aetiology of a thrombotic event

Determining risk of recurrence and therefore optimal duration of anticoagulation 194

Determining the need for primary prophylaxis in asymptomatic family members 195

Making decisions regarding the use of the oral contraceptive pill 196

Determining the need for thromboprophylaxis during pregnancy

Patients with arterial thrombosis

Potential detrimental effects of thrombophilia testing 197

Conclusion

References

CHAPTER 11 – PLATELETS IN THE PATHOGENESIS OF

VASCULAR DISEASE AND THEIR ROLE AS A THERAPEUTIC TARGET

*Sandeep Prabhu, Rahul Sharma,
Karlheinz Peter*

Introduction 201

Platelet function – Adhesion and activation

Platelet adhesion 202

Platelet activation 203

Mediators of platelet activation and ‘outside in’ signalling

Thrombin and collagen 204

Adenosine diphosphate (ADP)

Thromboxane A2 (TXA2)

Adrenaline 206

Second messenger systems 207

Physiological consequences of platelet activation

The GP IIb/IIIa receptor and ‘inside-out’ signalling

Granule exocytosis 208

Activation-induced conformational change of platelets

Platelets and atherosclerosis 209

Role of platelets in the initiation of the atherosclerosis

Role of the platelets in the progression of the atherosclerosis

Role of platelets in vulnerable plaques and plaque rupture

Current and future anti-platelet agents 210

Aspirin (salicylic acid)

Thienopyridines 211

Clopidogrel

Prasugrel 213

Ticlopidine

Ticagrelor

GPIIb/IIIa Antagonists

Other anti-platelet agents and promising new developments 214

Platelet function testing 215

Light-transmission aggregometry

Whole blood aggregometry 217
 VerifyNow® Assay
 Flow cytometry 218

References

CHAPTER 12 – PATHOGENESIS OF AORTIC ANEURYSMS

*Jonathan Golledge, Guo-Ping Shi,
 Paul E Norman*

Introduction 227

Differences between thoracic and abdominal aortic aneurysms 228

Summary of current theories and stages of AAA evolution

Atherosclerosis and AAA

Immune mechanisms in AAA 229

Extracellular matrix dysfunction 232

Infection 233

Biomechanical forces

Angiogenesis

Intra-luminal thrombus

Extracellular matrix proteolysis 234

Genetics 236

AAA rupture 237

Biomechanical factors in aneurysms rupture

The role of enzymes in AAA rupture

Role of intraluminal thrombus in aneurysm rupture 238

Future research

References

CHAPTER 13 – PHARMACOLOGICAL TREATMENT OF ANEURYSMS

Matthew Thompson, Janet T Powell

Background 247

Screening programmes

Pathophysiology 248

Therapeutic strategies

Beta blockade

Modification of the inflammatory

response 249

Non-steroidal anti-inflammatories

Matrix metalloproteinase (MMP)

inhibition

Anti-chlamydial therapy 250

Drugs acting on the renin/angiotensin axis

HMG Co-A reductase inhibitors 251

The future – Data from recent

experimental studies

References

CHAPTER 14 – PATHOPHYSIOLOGY OF AORTIC DISSECTION AND CONNECTIVE TISSUE DISORDERS

Mark Hamilton

Introduction 255

Embryology of thoracic aorta and arch vessels

Haemodynamics of thoracic compared to abdominal aorta 257

Sizes of normal aorta

Classification of aortic syndromes

Acute/Chronic

DeBakey classification of class 1 dissection – Type 1, 2, and 3

Stanford classification 258

European task force

Pathogenesis of thoracic aortic dissection

Classical thoracic aortic dissection (class 1 dissection) 260

Intramural haematoma (class 2 aortic dissection) 261

Penetrating aortic ulcer (class 4 aortic dissection) 262

Complications of acute aortic syndromes 263

Visceral ischaemia /malperfusion syndromes

Fate of the false lumen

Aneurysmal degeneration and rupture 264

Connective tissue disorders and acute aortic syndromes

Marfan syndrome	
Fibrillin and Marfan syndrome	265
The role of transforming growth factor beta in development of the vascular system in health and disease	266
Ehlers-Danlos syndrome	267
Diagnosis of Ehlers-Danlos syndrome	268
Loeys-Deitz syndrome	270
Familial thoracic aortic aneurysm disease	271
Bicuspid aortic valve	273
Turners Syndrome	
Summary	274
Reference list	

CHAPTER 15 – BIOMARKERS IN VASCULAR DISEASE

Ian M Nordon, Robert J Hinchliffe

Introduction	277
What is a biomarker?	
Types of biomarkers	
A classical clinical example	278
Potential value of biomarkers in vascular disease	279
Biomarker discovery steps	280
AAA biomarkers	
Circulating extracellular matrix markers	281
Matrix-degrading enzymes	283
Proteins associated with thrombosis	
Markers of inflammation	284
Biomarkers of AAA rupture	285
Biomarkers following endovascular repair	
Inflammation	287
Lipid accumulation	
Apoptosis	
Thrombosis	
Proteolysis	288
Challenges in biomarkers discovery	
Future work	
Conclusion	289
References	

CHAPTER 16 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VASCULITIS AND RAYNAUD'S PHENOMENON

Martin Veller

Vasculitides	295
Introduction	
Classification of vasculitides	296
Clinical presentation of vasculitides	
Investigations of vasculitides	
Principles of treatment of vasculitides	297
The vasculitides of specific interest to vascular surgeons	298
Giant cell arteritis	
Takayasu's arteritis	299
Thromboangitis obliterans (Buerger's disease)	300
Behcet's disease	301
Polyarteritis nodosa	302
Vasculitides secondary to connective tissue diseases	303
Systemic lupus erythematosus (SLE)	
Antiphospholipid antibody syndrome (APS)	304
Rheumatoid arthritis	305
Scleroderma	
Infective vasculitides	306
Human immunodeficiency virus (HIV)	
Pathophysiology and principles of Raynaud's phenomenon	307
Prevalence of Raynaud's phenomenon	308
Clinical findings in Raynaud's phenomenon	309
Diagnosis of Raynaud's phenomenon	
Prognosis	310
Treatment	
Recommendations	311
References	312

CHAPTER 17 – SIRS, SEPSIS AND

MULTIORGAN FAILURE*Vishwanath Biradar, John Moran***Epidemiology 315****Historical perspectives and definition 316****Risk factors for sepsis 317**

Causative agents

Pathophysiology of sepsis

innate immunity and toll-like receptors (TLRs) 319

Proinflammatory response

Coagulation cascade

Multorgan dysfunction syndrome (MODS) 320

Epithelial and endothelial dysfunction

Immune suppression and apoptosis

Sepsis, circulatory failure and organ dysfunction

Management 322

Steroids 323

Recombinant human activated protein C (rhAPC) 324

Glucose control 325

Renal replacement therapy

3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors (HMG-CoA) 326

Other adjuvant therapies in sepsis

Cytokines and anticytokine therapies

Pooled immunoglobulin (IVIG)

Acute respiratory distress syndrome (ARDS) 327

References**CHAPTER 18 –
PATHOPHYSIOLOGY OF
REPERFUSION INJURY***Prue Cowled, Rob Fitridge***Introduction 331****Ischaemia**

ATP and mitochondrial function

Gene expression during ischaemia 332

Reperfusion 333

Reactive oxygen species

Eicosanoids 334

Nitric Oxide 335

Endothelin 336

Cytokines

Neutrophil and endothelial interactions 338

Complement activation 340

Tissue destruction 341

Proteases and metalloproteinases

Apoptotic cell death during ischaemia-reperfusion injury

No-reflow phenomenon 342

Therapeutic approaches to IRI

Ischaemic preconditioning

Ischaemic post-conditioning 343

Conditioning effects of volatile anaesthetics

Pharmacological treatments 344

Summary 345**References****CHAPTER 19 – COMPARTMENT
SYNDROME***Edward Choke, Robert Sayers, Matthew Bown***Definition 351****Acute limb compartment syndrome**

Incidence

Anatomy/physiology 352

Aetiology/pathophysiology

Clinical presentation 354

Investigation 355

Treatment 357

Complication of LCS 359

Outcome 360

Acute abdominal compartment syndrome

Incidence 361

Aetiology

Pathological effects of raised intra-abdominal pressure 362

Clinical presentation 363

Investigation

Treatment 364

Complications of surgical decompression

Outcome 367

References 368

CHAPTER 20 – PATHOPHYSIOLOGY OF PAIN

Stephan Schug, Helen Daly, Kathryn Stannard

Introduction 375

Peripheral mechanisms

Nociception/transduction

Conduction 376

Spinal cord mechanisms

Ascending systems 377

Descending control

Pain modulation 378

Peripheral sensation

Central sensitisation in the dorsal horn

Neuropathic pain 379

Mechanisms of neuropathic pain

Peripheral mechanisms

Spontaneous ectopic discharge

Altered gene expression

Spared sensory neurons

Involvement of the sympathetic nervous system 380

Collateral sprouting

Effects of bradykinin

Central mechanisms

Wind up

Central sensitization 381

Central disinhibition

Expansion in receptive field size (recruitment)

Immediate early gene expression

Anatomical re-organisation of the spinal cord

Contribution of glial cells to pain conditions 382

Symptoms of neuropathic pain

Stimulus-dependent pain

Stimulus-independent pain 383

Sympathetically maintained pain (SMP)

Neuropathic pain syndromes

Peripheral neuropathies

Central neuropathies 385

References

CHAPTER 21 – POST-AMPUTATION PAIN

Stephan Schug, Gail Gillespie

Introduction 389

Classification and incidence of post-amputation pain syndromes

Stump pain

Phantom sensation 390

Phantom limb pain

Pathophysiology of post-amputation pain syndromes

Peripheral factors

Spinal factors 391

Supraspinal factors

Current pathophysiological model of post-amputation pain syndromes 392

Prevention of post-amputation pain

Perioperative lumbar epidural blockade

Peripheral nerve blockade 393

NMDA antagonists

Evaluation of the patient with post-amputation pain syndromes

Examination

Therapy of post-amputation pain syndromes 394

Calcitonin

Ketamine

Analgesic and Co-analgesic compounds

Opioids 395

Gabapentin

Clonazepam

Lidocaine

Carbamazepine

Tricyclic antidepressants (TCA)

Selective serotonin reuptake inhibitors

Baclofen

Capsaicin

Symptomatic treatment of pain components 396

Neuropharmacological therapies

Invasive therapies
 Electroconvulsive therapy (ECT)
 Nerve blockade
 Spinal cord stimulation
 Implantable intrathecal delivery systems
 Dorsal root entry zone (DREZ) lesions
 Psychological therapy 397
Future aims
References

CHAPTER 22 – TREATMENT OF NEUROPATHIC PAIN

Stephan Schug, Kathryn Stannard

Introduction 401
Principles of treatment
Pharmacological treatment 402
 Opioids
 Recommendations for clinical use of opioids
 Tramadol
 Mechanism of action
 Efficacy 403
 Adverse effects
 Recommendations for clinical use of tramadol in neuropathic pain
 Antidepressants
 Tricyclic antidepressants (TCAs)
 Mechanism of action 404
 Adverse effects
 Selective serotonin re-uptake inhibitors (SSRIs)
 Serotonin/Noradrenaline reuptake inhibitors (SNRIs) 405
 Recommendations for clinical use of antidepressants as analgesics
 Anticonvulsants
 Mechanism of action 406
 Individual medications
 Clonazepam
 Gabapentin
 Pregabalin 407
 Carbamazepine
 Sodium valproate 408

Phenytoin
 Lamotrigene
 Recommendations for clinical use of anticonvulsants as analgesics
 Local anaesthetics and antiarrhythmics 409
 Mechanism of action
 Lignocaine
 Mexiletine
 Recommendations for clinical use of lignocaine and mexiletine in neuropathic pain
 N-methyl-D-aspartate-receptor antagonists (NMDA)
 Ketamine 410
 Other NMDA antagonists
 Miscellaneous compounds for systemic use
 Clonidine
 Efficacy
 Baclofen
 Levodopa 411
 Cannabinoids
 Topical treatments
 Lignocaine 5% medicated plaster
 Capsaicin 412
 Mechanism of action
 Efficacy
Non-pharmacological therapy
 Transcutaneous electrical nerve stimulation (TENS)
 Spinal cord stimulation (SCS) 413
 Sympathetic nerve blocks
 Neurosurgical destructive techniques
 Cognitive behaviour therapy
References 414

CHAPTER 23 – PRINCIPLES OF WOUND HEALING

Gregory Schultz, Gloria Chin, Lyle Moldawer, Robert Diegelmann

Introduction 423
Phases of acute wound healing
 Haemostasis

- Inflammation 426
 - Neutrophils 427
 - Macrophages 428
- Proliferative phase 429
 - Fibroblast migration 430
 - Collagen and extracellular matrix production
 - Angiogenesis 431
 - Granulation 432
 - Epithelialization
 - Remodelling 433
- Summary of acute wound healing 435
- Comparison of acute and chronic wounds**
 - Normal and pathological responses to injury
 - Biochemical differences in the molecular environments of healing and chronic wounds 436
 - Biological differences in the response of chronic wound cells to growth factors 439
- From bench to bedside**
 - Role of endocrine hormones in the regulation of wound healing
 - Molecular basis of chronic non-healing wounds
 - Chronic venous stasis ulcers 441
 - Pressure ulcers
- Future concepts for the treatment of chronic wounds 442**
 - Bacterial biofilms in chronic wounds 443
- Conclusion 445**
- References**

CHAPTER 24 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VARICOSE VEINS

Andrew Bradbury

- Introduction 451**
- Anatomy**
- Histology 452**
- Physiology**

- Varicose veins 453**
- Valvular abnormalities**
- Muscle pump failure 455**
- Venous recirculation**
- Recurrent varicose veins**
 - New varicose veins
 - Persistent varicose veins
 - True recurrent varicose veins 456
- Cellular and molecular biology of varicose veins**
- Conclusion 457**
- References**

CHAPTER 25 – CHRONIC VENOUS INSUFFICIENCY AND LEG ULCERATION: PRINCIPLES AND VASCULAR BIOLOGY

Michael Stacey

- Definitions 459**
 - Chronic venous insufficiency
 - Leg ulceration
 - Assessment of cause of leg ulceration 460
- Epidemiology 461
- Pathophysiology
 - Venous abnormality
 - Effect of ambulatory venous hypertension on the tissues in the leg 463
 - Influence of venous disease on the wound healing process 465
 - Genetic associations with venous ulceration 466
- Assessment of venous function 467**
- Treatment of venous ulceration**
 - Compression therapy
 - Dressings 468
 - Surgery
 - Prevention of venous ulcer recurrence 470
 - Sclerotherapy and other techniques to obliterate surface and perforating veins
 - Other therapies 471
- References**

CHAPTER 26 –
PATHOPHYSIOLOGY AND
PRINCIPLES OF MANAGEMENT
OF THE DIABETIC FOOT

*David Armstrong, Timothy Fisher, Brian
Lepow, Matthew White, Joseph Mills*

- Introduction** 475
- Pathophysiology of the diabetic foot** 476
- Neuropathy
 - Structural abnormalities/gait abnormalities
 - Angiopathy 478
- Diagnosis**
- History and rapid visual screening
 - Neurological examination 479
 - Monofilament testing
 - Vibration testing
 - Dermatologic examination 480
 - Anatomy of occlusive disease – vascular examination
 - Prediction of wound healing: assessment of perfusion 481
 - Arterial imaging
 - Soft tissue imaging 482
- Classification systems** 483
- Diabetes mellitus foot risk classification
 - University of Texas wound classification system
- Clinical problems and principles of management** 484
- Ulceration
 - Epidemiology and risk factors
 - Offloading
 - Non-vascular surgical treatment 485
 - Class I – Elective 486
 - Class II – Prophylactic
 - Class III – Curative
 - Class IV – Emergency (urgent)
 - Post-operative management
 - Infections 487
 - Charcot arthropathy
- Prevention** 490
- Conclusion** 492
- References**

CHAPTER 27 – LYMPHOEDEMA
– PRINCIPLES, GENETICS AND
PATHOPHYSIOLOGY

Matt Waltham

- Introduction** 497
- Classification of lymphoedema**
- Classification of primary lymphoedema 498
- The genetics of lymphangiogenesis in primary lymphoedema** 500
- Milroy's disease
 - Lymphoedema – distichiasis syndrome 501
 - Hypotrichosis – lymphoedema – telangiectasia syndrome 502
 - Meige disease (primary non-syndromic lymphoedema)
 - Other primary lymphoedema disorders 503
- Structure and development of the lymphatic circulation**
- Clinical aspects of lymphoedema** 505
- Summary**
- References**

CHAPTER 28 – GRAFT
MATERIALS PAST AND FUTURE

Mital Desai, George Hamilton

- The pathophysiology of graft healing** 511
- The peri-anastomotic area
 - Healing of prosthetic grafts 512
 - The healing process of the anastomosis
 - Graft porosity and permeability
- Physical properties of prosthetic materials** 514
- Tubular compliance
 - Anastomotic compliance mismatch
 - The compliance hypothesis of graft failure
- Synthetic grafts** 515
- Newer developments of Dacron grafts
 - Modifications and newer developments of PTFE grafts 517
 - Polyurethane grafts

Newer developments of polyurethane vascular grafts	518
Biological vascular grafts	519
Newer developments of biological vascular grafts	520
Prosthetic graft modifications	
Modifications to reduce graft infection	
Modifications to improve patency	521
Nanocomposite grafts	
Endothelial cell seeding	522
Single stage seeding	
Two stage seeding	
Vascular tissue engineering	
Non-degradable polymer and cell seeding	523
Bioresorbable and biodegradable polymers	
Combined bioresorbable and tissue engineered grafts	524
Mechanical conditioning of seeded vascular cells	
Alternative scaffolds	
Tissue-engineered grafts	525
Graft materials for aortic endografts	526
The future	
References	527

CHAPTER 29 – PATHOPHYSIOLOGY OF VASCULAR GRAFT INFECTIONS

Mauro Vicaretti

Introduction	537
Natural history of prosthetic vascular graft infections	
Mechanism of graft contamination at operation	538
Pathogenesis of graft infections	
Bacteriology of vascular graft infections	
Investigations for detection of prosthetic graft infections	539
History and physical examination	
Laboratory investigations	
Diagnostic imaging	540
Management of prosthetic graft infections	
Prevention	
Reduction of prosthetic vascular graft infection with rifampicin bonded gelatin sealed Dacron	541
Established infection	
Antibiotic therapy	
Operative management	
Conclusion	542
References	

Acknowledgements

The Editors gratefully acknowledge the outstanding contributions of each Author involved in this reference book. We would also like to acknowledge the invaluable efforts of Ms Sheona Page who has worked tirelessly on this project. We would also like to thank Prue Cowled PhD and Ms Cayley Wright for their assistance.

Abbreviation List

a1-PI	a1-protease inhibitor
5-HT	5-Hydroxytryptamine/Serotonin
AAA	Abdominal aortic aneurysm
AAS	Acute aortic syndrome
AAV	Adeno-associated viruses
ACE	Angiotensin converting enzyme
ACS	Acute coronary syndrome
ACS	Abdominal compartment syndrome
ACTH	Adrenocorticotrophic hormone
ADAMTS	A disintegrin and metalloproteinase with thrombospondin motifs
ADP	Adenosine diphosphate
AIDS	Acquired immune deficiency syndrome
ALI	Acute lung injury
AMP	Adenosine monophosphate
AMPA	α -amino-3 hydroxy-5-methylisoxazole
ANA	Anti-nuclear antibody
ANCA	Anti-neutrophil cytoplasmic antibody
AOD	Aortic occlusive disease
AP1	Activated protein 1
APC	Activated protein C
APC	Antigen presenting cell
APLAS	Antiphospholipid antibody syndrome
ApoAI	Apolipoprotein AI
ApoE	Apolipoprotein E
APS	Antiphospholipid antibody syndrome
APTT	Activated partial thromboplastin time

ARDS	Acute respiratory distress syndrome
AT	Antithrombin
ATP	Adenosine triphosphate
AVP	Ambulatory venous thrombosis
β 2-GPI	β 2-glycoprotein Ib
bFGF	Basic fibroblast growth factor
BKCa	Large conductance calcium activated potassium channel
BMPs	Bone morphogenetic proteins
BMS	Bare metal stent
CAD	Coronary artery disease
CaM	Calmodulin
CAM	Cell adhesion molecule
cAMP	Cyclic adenosine monophosphate
CCK	Cholecystokinin
cGMP	Cyclic guanine monophosphate
CD	Cluster of differentiation
CD40L	Cluster of differentiation 40 ligand
CEA	Carotid endarterectomy
CETP	Cholesteryl ester transfer protein
CFD	Computational fluid dynamics
CG	Cationized gelatin
CGRP	Calcitonin gene regulated peptide
CHD	Coronary heart disease
CI	Confidence interval
CIMT	Carotid intimal-media thickness
c-JNK	c-Jun N-terminal kinase
CK-MB	Creatinine kinase (Myocardial specific)
CNCP	Chronic noncancer pain
cNOS	Constitutive nitric oxygen synthase enzyme
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
CROW	Charcot restraint orthotic walker
CRRT	Continuous renal replacement therapy

CRP	C-reactive protein
CRPS	Complex regional pain syndromes
CT	Computational tomography
CTA	Computed tomographic angiography
CTD	Connective tissue disorders
CTGF	Connective tissue growth factor
CYP	Cytochrome P450
CVD	Cardiovascular disease
CVI	Chronic venous insufficiency
DAG	Diacylglycerol
DES	Drug-eluting stent
DRG	Dorsal root ganglion
DNA	Deoxyribonucleic acid
DSA	Digital subtraction arteriography
DTS	Dense tubular system
DVT	Deep vein thrombosis
EC	Endothelial cell
ECM	Extracellular matrix
EDCF	Endothelium-derived contracting factor
EDH	Endothelium-dependent hyperpolarisation
EDS	Ehlers-Danlos syndrome
EET	Epoxyeicosatrienoic acids
ELAM-1	Endothelial-leukocyte adhesion molecule-1
ELG	Endoluminal grafts
ELISA	Enzyme linked immunosorbent assay
E_K	Equilibrium potential
E_M	Membrane potential
eNOS	Endothelial nitric oxide synthase enzyme
EPC	Endothelial progenitor cells
EPCR	Endothelial protein C receptor
ePTFE	Expanded polytetrafluoroethylene
ERK	Extracellular signal-regulated kinase
ESR	Erythrocyte sedimentation rate

ET	Essential thrombocytosis
ET-1	Endothelin 1
EVAR	Endovascular aortic aneurysm repair
EVLA	Endovenous LASER ablation
FDA	Food and drug administration
FDPs	Fibrin degradation products (soluble)
FGF	Fibroblast growth factor
FGF-2	Fibroblast growth factor 2
FMN	Flavin mononucleotide
FVL	Factor V Leiden
GABA	Gamma-aminobutyric acid
GABA B	Gamma-aminobutyric acid subtype B
G-CSF	Granulocyte colony stimulating factor
GMCSF	Granulocyte-macrophage colony stimulating factor
GP	Glycoprotein
GPCR	G-protein coupled receptor
GSV	Great saphenous vein
HDL	High density lipoprotein
HDL-C	High density lipoprotein cholesterol
HIF	Hypoxia inducible factor
HIT	Heparin induced thrombocytopenia
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HMG Co-A	Hydroxymethylglutaryl coenzyme-A
HMW	High molecular weight
HPETE	Hydroperoxyeicosatetraenoic acid
HETE	Hydroxyeicosatetraenoic acids
HR	Hazard ratio
hsCRP	High-sensitive C-reactive protein
HSP	Heat shock protein
HUV	Human umbilical vein
IAH	Intra-abdominal hypertension

IAP	Intra-abdominal pressure
IAPP	Intra-abdominal perfusion pressure
ICAM-1	Inter-cellular adhesion molecule-1
ICAM-2	Inter-cellular adhesion molecule-2
ICP	Intra-compartmental pressure
ICU	Intensive care unit
IFN	Interferon
IGF-1	Insulin-like growth factor-1
IHD	Ischemic heart disease
IL	Interleukin
IL-1	Interleukin-1
IL-1 α	Interleukin-1 alpha
IL-1 β	Interleukin-1 beta
IL-6	Interleukin-6
IL-8	Interleukin-8
ILT	Intraluminal thrombus
IKCa	Intermediate conductance calcium-activated potassium channels
IMH	Intramural haematoma
IMP	Inosine monophosphate
iNOS	Inducible nitric oxide synthase enzyme
IP(3)	1,4,5-inositol triphosphate
IRI	Ischemia reperfusion injury
IVIG	Intravenous pooled immunoglobulin
IVUS	Intravascular ultrasound
KGF	Keratinocyte growth factor
KGF-2	Keratinocyte growth factor-2
LAP	Latency associated peptide
LCS	Limb compartment syndrome
LDL	Low density lipoprotein
LDS	Loeys-Dietz syndrome
LLC	Large latent complex
LEC	Lymphatic endothelial cells

LFA-1	Lymphocyte function-associated antigen-1
LO	Lipoxygenase
LOX	Lysyl oxidase
LOPS	Loss of protective sensation
LPA	Lysophosphatidic acid
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
LTGFBP	Latent TGF binding protein
MAC-1	Macrophage-1 antigen
MAPK	Mitogen activated protein kinase
MCP-1	Monocyte chemoattractant protein-1
M-CSF	Macrophage-colony stimulating factor
MFS	Marfan syndrome
MHC	Major histocompatibility
MI	Myocardial infarction
MIP-1	Macrophage inflammatory protein-1
MLC ₂₀	Myosin light chain ₂₀
MLCK	Myosin light chain kinase
MLCP	Myosin light chain phosphatase
MMP	Matrix metalloproteinase
MODS	Multiple organ dysfunction syndrome
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
mRNA	Messenger RNA
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
MRSE	Methicillin resistant <i>Staphylococcus epidermidis</i>
MRTA	Magnetic resonance tomographic angiography
MTHFR	Methylenetetrahydrofolate reductase
MT-MMP	Membrane-type MMP
MVPS	Mitral valve prolapse syndrome
NADPH	Nicotinamide adenine dinucleotide phosphate
NGF	Nerve growth factor

NFκB	Nuclear factor kappa B
NiTi	Nitinol
NJP	Non-junctional perforators
NMDA	N-methyl-D-aspartate
NNH	Number needed to harm
NNT	Number needed to treat
NO	Nitric oxide
NOS	Nitric oxide synthase enzyme
NSAID	Non-steroidal anti-inflammatory drug
NV	Neovascularisation
OCP	Oestrogen/progesterone contraceptive pill
OPN	Osteopontin
OPG	Osteoprotegerin
OR	Odds ratio
OxLDL	Oxidised low density lipoprotein
PAD	Peripheral arterial disease
PAF	Platelet activating factor
PAI	Plasminogen activator inhibitor
PAI-1	Plasminogen activator inhibitor-1
PAR	Protease activated receptor
PAR-1	Protease activated receptor-1
PAR-4	Protease activated receptor-4
PAU	Penetrating aortic ulcer
PC	Protein C
PCA	Poly (carbonate-urea) urethane
PCI	Percutaneous coronary intervention (angioplasty)
PCWP	Pulmonary capillary wedge pressure
PDGF	Platelet-derived growth factor
PDGFβ	Platelet-derived growth factor-β
PDS	Polydioxanone
PECAM-1	Platelet-endothelial cell adhesion molecule-1
PEDF	Pigment epithelium-derived factor
PES	Paclitaxel-eluting stent

PET	Positron emission tomography
PF4	Platelet factor 4
PGI ₂	Prostacyclin
PGG ₂	Prostaglandin G ₂
PGH ₂	Prostaglandin H ₂
PGEI ₂ /PGI ₂	Prostaglandin I ₂
PGN	Peptidoglycan
PHN	Postherpetic neuropathy
PHZ	Para-anastomotic hyper-compliant zone
PI3K	Phosphatidylinositol 3-kinase
PIP2	Phosphatidylinositol 4,5-bisphosphate
PLC	Phospholipase C
PLOD	Procollagen lysyl hydroxylase
PMCA	Plasma membrane Ca ²⁺ APTases
PMN	Polymorphonuclear leukocyte
POSS	Polyhedral oligomeric silsesquioxanes
PPAR	Peroxisomal proliferation activating receptor
PPI	Proton pump inhibitor
PRV	Polycythaemia rubra vera
PS	Protein S
PSGL-1	P-selectin glycoprotein ligand-1
PT	Prothombin time
PTCA	Percutaneous coronary angioplasty
PTFE	Polytetrafluoroethylene
PTS	Post-thrombotic syndrome
PUFA	Polyunsaturated fatty acid
PVI	Primary valvular incompetence
rAAA	Ruptured AAA
Rac	Ras activated cell adhesion molecule
RANTES	Regulated upon activation, normal T cell expressed and secreted
RAS	Renin angiotensin system
RCT	Randomised controlled trial

RF	Rheumatoid factor
RFA	Radiofrequency ablation
rhAPC	Recombinant human activated protein C
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RR	Relative risk
RSD	Reflex sympathetic dystrophy
S1P	Sphingosine-1-phosphate
SAPK	Stress-activated protein kinase
SCF	Stem cell factor
SCS	Spinal cord stimulation
ScvO2	Superior vena cava venous oxygen saturation
SDF-1	Stromal-cell-derived factor-1
SERCA	Sarco/endoplasmic reticulum CaATPases
SEP	Serum elastin peptides
SES	Sirolimus-eluting stent
SEPS	Subfascial endoscopic perforator surgery
SFA	Superficial femoral artery
SFJ	Sapheno-femoral junction
SIRS	Systemic inflammatory response syndrome
SKCa	Small conductance calcium-activated potassium channels
SLE	Systemic lupus erythematosus
SMA	Smooth muscle alpha actin
SMC	Smooth muscle cell
SMP	Sympathetically maintained pain
SNARE	Soluble N-ethylmaleimide-sensitive factor activating protein receptors
SNP	Single nucleotide polymorphisms
SNRI	Serotonin/Noradrenaline reuptake inhibitors
SPJ	Sapheno-popliteal junction
SPP	Skin perfusion pressure
SR	Sarcoplasmic reticulum
SSRIs	Selective serotonin re-uptake inhibitors
SSV	Small saphenous vein

SVT	Superficial thrombophlebitis
STIM1	Stromal interacting molecule 1
T α CE	TNF α converting enzyme
TAAD	Thoracic aortic aneurysm disease
TAD	Thoracic aortic dissection
TAFI	Thrombin-activatable fibrinolysis inhibitor
Tc-99 MDP	Technetium-99 methylene diphosphonate
TCA	Tricyclic antidepressant
TCC	Total contact cast
TCR	T-cell receptor
TENS	Transcutaneous electrical nerve stimulation
TF	Tissue factor
TFPI	Tissue factor pathway inhibitor
TGF	Transforming growth factor
TGF- α	Transforming growth factor-alpha
TGF- β	Transforming growth factor-beta
TGL	Triglycerides
Th	T helper
TIA	Transient ischemic attack
TIMP	Tissue inhibitors of metalloproteinase
TLR	Toll-like receptors
TNF	Tumour necrosis factor
TNF- α	Tumour necrosis factor-alpha
tPA	Tissue-type plasminogen activator
TRP	Transient receptor potential
TRPC	Transmembrane receptor potential canonical
TRPV1	Transmembrane receptor potential Vanilloid-type
TXA2	Thromboxane A2
uPA	Urokinase
UT	University of Texas
VCAM	Vascular cell adhesion molecule
VCAM-1	Vascular cell adhesion molecule-1
VEGF	Vascular endothelial growth factor

VEGF-R	Vascular endothelial growth factor receptor
VIP	Vasoactive intestinal peptide
VLA-1	Very late activating antigen-1
VOCC	Voltage operated calcium channels
VPT	Vibratory perception threshold
VSMC	Vascular smooth muscle cells
VTE	Venous thromboembolism
VV	Varicose veins
vWF	von Willebrand factor
XO	Xanthine oxidase

22 • Treatment of Neuropathic Pain

STEPHAN A SCHUG¹, KATHRYN JD STANNARD²

School of Medicine and Pharmacology, University of Western Australia,
Royal Perth Hospital, Perth, Western Australia.

INTRODUCTION

Neuropathic pain is defined by The International Association for the Study of Pain (IASP) as pain following a primary lesion or dysfunction of the nervous system.¹ It is caused either by peripheral damage with lesions involving peripheral nerves, dorsal root ganglia and the dorsal roots (peripheral neuropathic pain) or by central damage, which may involve injury caused by infarction or trauma of spinal cord or brain (central neuropathic pain).

Neuropathic pain results in persistent pain syndromes that have no biological function, but are difficult to treat and cause great distress to the individual. Neuropathic pain is also referred to as neurogenic pain, deafferentation pain, neuralgia, neuralgic pain and nerve pain.

Neuropathic pain may develop immediately after a nerve injury or after a variable interval. It may be maintained by factors different from the initial cause. It can persist for a long time and is frequently not explained by underlying pathology. Patients are frequently seen by many different specialists and their treatment often fails to resolve the pain. As the pain persists other factors such as environmental, psychological and social

stressors become relevant contributors to the overall presentation.

PRINCIPLES OF TREATMENT

Treatment of neuropathic pain is not straightforward. The pain is often refractory to conventional analgesic regimens such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Opioids have only limited efficacy in neuropathic pain as outlined later in this chapter; therefore so called co-analgesics, medications which are not typically used as analgesics, are often the first-line treatment of neuropathic pain.

Increasingly, data from randomised controlled trials (RCTs) and meta-analyses are leading to improvements in management and a more evidence-based approach. A number of recent evidence-based guidelines have been published by various societies and organisations. Of particular value are the guidelines published by the European Federation of Neurological Societies (EFNS)² and by the Special Interest Group Neuropathic Pain of the IASP (NeuPSIG).³

It is important that patients have realistic expectations regarding treatment efficacy and potential side effects in order to improve

compliance with medication.⁴ A balance between these should be achieved on an individual basis. A single drug therapy should be tried before combinations of drugs are started. Non-pharmacological treatments are available that may be appropriate for certain cases. For optimal results a multidisciplinary approach to treatment should be adopted that addresses affective and behavioural changes and disability.

PHARMACOLOGICAL TREATMENT

Opioids

The use of opioids to treat neuropathic pain is controversial. In 1988 a study implied that patients with neuropathic pain did not experience pain relief from opioids.⁵ However, this study has been criticised for possible selection bias as most non-responders had previously used morphine without effective results and there was no individual titration of morphine. A number of reasons have been suggested for the relative opioid resistance; these include among others, down-regulation of peripheral and spinal opioid receptors^{6,7} and physiological antagonism with up-regulation of cholecystikinin.⁸ There is also evidence in animal experiments that long term use of opioids induces a state of CNS hyperexcitability implying that tolerance to opioids may have a pharmacology similar to hyperalgesia.⁹ Studies in humans have so far not confirmed these experimental data.

Since then multiple RCTs in neuropathic pain have been conducted with morphine, fentanyl, oxycodone and other opioids. The general consensus is that pain intensity may be relieved by opioids titrated for that individual. This concept was confirmed in a study in which dose responses of opioids in nociceptive and neuropathic pain were

compared and higher doses were indeed required in neuropathic pain.¹⁰ A Cochrane Review of the multiple RCTs confirmed significant efficacy of opioids in neuropathic pain.¹¹

Recommendations for clinical use of opioids in neuropathic pain

There is now a general consensus that a subset of patients with neuropathic pain benefit from treatment with opioids.¹² However, current guidelines for neuropathic pain treatment do not recommend opioids as a first-line option due to the potential adverse effects and risks of these drugs.^{2,3} If a decision to use opioids is made, then the approach to identify these patients and manage their treatment should follow guidelines for the use of opioids in chronic noncancer pain (CNCP).^{13,14}

Summarising such guidelines is beyond the scope of this chapter; in brief they usually include a past/present history of drug addiction as a relative contraindication, the need for regular follow-up visits and opioids to be prescribed and supervised by the same doctor. Legal issues with opioid prescriptions are associated with their controlled status, the risk of addiction and abuse and the potential for diversion into illegal channels by selling or passing on to others.¹⁵ Methadone, due to its additional monaminergic and NMDA receptor effects, might be a particularly useful opioid in the setting of neuropathic pain.^{16,17}

Tramadol

Mechanism of action

Tramadol is a centrally acting synthetic analogue of codeine; however it is not a conventional opioid as it has relatively low affinity for μ -opioid receptors and is classified by the FDA as an atypical centrally acting analgesic. Tramadol together with its primary active metabolite has

three synergistic mechanisms of action to provide analgesia. It combines weak effects on opioid receptors with monoaminergic mechanisms. Reuptake inhibition of 5-HT and noradrenaline contribute to the antinociceptive action of tramadol.^{18,19} Tramadol is a racemic mixture with opioid receptor activity and 5-HT reuptake inhibition mainly associated with the (+)-tramadol enantiomer, whereas (-)-tramadol is a reuptake inhibitor of noradrenaline.^{20,21} The monoaminergic effects suggest a higher analgesic potency of tramadol in neuropathic than in nociceptive pain states; this has been recently confirmed by our group.²²

Efficacy

Tramadol has been investigated for the treatment of chronic pain in the past. A number of RCTs of tramadol in patients with neuropathic pain have been completed. The first involved 131 patients with diabetic neuropathic pain, 37% patients withdrew, more from adverse effects in the tramadol group and more from lack of efficacy in the placebo group. The tramadol group had significantly more pain relief than placebo.²³ In a subsequent randomised placebo-controlled crossover trial 45 patients with neuropathic pain were studied. Significant reductions in spontaneous and touch-evoked pain were achieved with tramadol.²⁴

A meta-analysis of these and other RCTs identified tramadol as an effective treatment for neuropathic pain; or with number needed to treat (NNT) for 50% pain relief of 3.8 with therapeutic effects on paraesthesia and allodynia and a number needed to harm (NNH) of 8.3.²⁵

Adverse effects

Tramadol causes less respiratory depression²⁶ and constipation²⁷ than conventional opioids. Physical dependence to tramadol use is extremely rare²⁸ and occurs in the range of

1:100,000 users.²⁹ Similarly, tramadol has a low abuse potential³⁰ and its risk of addiction has been rated in the range of 1:100,000.^{29,31} For these reasons, tramadol is not under special regulatory control in most countries. Phase IV clinical trials have reported the overall incidence of side-effects from tramadol to be 15.3%.³² The majority of side-effects were found to be dose dependent.

Recommendations for clinical use of tramadol in neuropathic pain

Experimental evidence and a meta-analysis have shown tramadol to be a particularly useful analgesic in neuropathic pain with a low incidence of adverse effects, mainly of a benign nature. In our experience (and that of many other pain clinics) it is the preferred opioid-like drug in this indication, in particular as a background analgesic in a slow-release preparation. However, it is not a first-line drug in neuropathic pain.^{2,3}

Antidepressants

Tricyclic antidepressants (TCAs)

In 1960 Paoli *et al* made the incidental discovery that the tricyclic antidepressant (TCA) imipramine had an analgesic effect.³³ Since then other TCAs and other antidepressants have been evaluated and used for the treatment of neuropathic pain. TCAs are the first class of medication to be proven to be effective for neuropathic pain in a double blind placebo controlled trial.³⁴ The role of TCAs in the treatment of neuropathic pain is now well established and has the best documented evidence.³⁵ The overall NNT for neuropathic pain is 3.6 with better efficacy in diabetic neuropathy than in postherpetic neuralgia (PHN).

Amitriptyline is established as the 'gold standard' as it has the most evidence available, especially for the treatment of painful diabetic neuropathy and PHN.³⁶ However,

amitriptyline and other TCAs have also been evaluated for the relief of pain in peripheral neuropathies and central post stroke pain. In comparative trials no single TCA has been found to be superior for neuropathic pain except in PHN where amitriptyline was found to be superior to maprotiline.³⁴

Mechanism of action

Initially it was thought that the analgesic action of TCAs was related to their antidepressant activity. However, it is now clear that there is an independent specific analgesic effect, as the doses used to relieve neuropathic pain are smaller and the onset of analgesic efficacy is faster than an antidepressant effect and analgesia does not appear to depend upon mood improvement in depressed patients.^{37,38} In addition, pain relief was found to be independent of any sedative effect.

TCAs are inhibitors of the reuptake of monoaminergic transmitters and this mechanism mediates their analgesic effect by the following presumed mechanisms:³⁶

- 1) Central blockade of monoamine re-uptake, particularly serotonin and noradrenaline, leads to enhancement of the descending inhibitory monoaminergic pathways in the dorsal horn of the spinal cord.
- 2) Anticholinergic activity reduces firing of central neurones involved in pain, especially after deafferentation.

Additionally there may be a number of other contributing mechanisms: moderation of NMDA receptor activity, opioid receptor activity, increase in dopamine or endorphin levels, blockade of central or peripheral histamine receptors, sodium channel blockade and blockade of adrenergic receptors on regenerating sprouts.^{36,39}

Adverse effects

The optimum analgesic dose of TCAs can often not be reached due to unpleasant side effects. A systematic review of randomised controlled trials of TCAs used to treat neuropathic pain found that out of 100 patients, 30 had significant pain relief, 30 had minor side effects and 40 had to discontinue their therapy due to side effects.⁴⁰ These include:

- 1) Anticholinergic: dry mouth, constipation, urinary retention and blurred vision.
- 2) Antihistaminergic: confusion and sedation (the latter may be of benefit)
- 3) Anti α -adrenergic: postural hypotension and sexual dysfunction.

Cardiac conduction abnormalities may also arise due to the muscarinic anticholinergic actions. Patients at risk should have a pre-treatment ECG as cardiac conduction defects are a contraindication to treatment with TCAs. Another potential problem is overdose where TCAs are more dangerous than other groups of antidepressants and maybe fatal due to severe cardiac arrhythmias and convulsions.

Desipramine, imipramine and nortriptyline are more specific to noradrenergic blockade and are associated with less anticholinergic and antihistamine side effects. They may be useful in patients who are not able to tolerate amitriptyline, before progressing to another class of drug. In PHN and painful diabetic neuropathy, they were both found to be as effective as amitriptyline,^{34,37,41} but associated with less side effects. Physical withdrawal reactions have been described for most antidepressants, but psychological addiction is not an issue.³⁶

Selective serotonin re-uptake inhibitors (SSRIs)

Selective serotonin re-uptake inhibitors such as fluoxetine and paroxetine have only

limited efficacy in neuropathic pain.³⁵ They alter serotonergic (5-HT) far more than noradrenergic (NE) neurotransmission. However, due to their selectivity they do not interfere as much with adrenergic, histaminergic or muscarinic receptors and therefore have fewer side effects. There is currently insufficient evidence to make generalisations regarding their use in this indication.⁴²

Serotonin/Noradrenaline reuptake inhibitors (SNRIs)

Venlafaxine and duloxetine are novel antidepressants, which belong to the class of SNRIs. They have similar mechanisms of action as TCAs, but no anticholinergic effects. While data on venlafaxine are currently inconclusive, duloxetine has indications in the treatment of diabetic polyneuropathy (NNT = 6) and fibromyalgia (NNT = 8) and is approved for this indication in some countries.⁴³ There are no direct comparisons to other antidepressants published, but SNRIs are thought to be better tolerated than TCAs.

Recommendations for clinical use of antidepressants as analgesics

Evidence-based decisions to use antidepressants in neuropathic pain states are usually based on a NNT approach.^{35,43,44}

- TCAs for PHN: NNT 2.7
- TCAs for atypical face pain: NNT 2.8
- TCAs for diabetic neuropathy: NNT 1.3
- Duloxetine for diabetic neuropathy: NNT 5.8 - 6

It is difficult to generalise a dosage regimen for antidepressants in neuropathic pain, due to significant inter-individual variability.⁴⁵ McQuay *et al* have demonstrated a dose response relationship for amitriptyline with a greater analgesic response at 75mg/d than 25 or 50mg/d.⁴⁶

Current recommendations for prescribing TCAs are:⁴

- 1) Start with a low dose (5–10mg/d) especially in the elderly and increase this weekly to analgesic efficacy or unacceptable side effects.
- 2) Once the optimal dose is achieved analgesic efficacy usually takes up to a week to achieve.
- 3) There have not been any trials conducted for longer than 6 weeks, so there is no evidence base for optimum duration of treatment. The current practice is to continue the same effective dose for several months and then to try and reduce it.
- 4) If a therapeutic dose of a TCA fails to provide pain relief, other antidepressants are also likely to fail.
- 5) If a TCA provides pain relief at the expense of unacceptable side effects then other antidepressants (in particular SNRIs) with a lower side effect profile should be tried.
- 6) If due to contraindications or unacceptable side effects a patient is unable to be treated with TCAs, other antidepressants (in particular SNRIs) should be tried before excluding this drug category.

Anticonvulsants

In the 1960s phenytoin was found to have an analgesic effect in the treatment of painful diabetic neuropathy.⁴⁷ Since then anticonvulsants have been evaluated and used in neuropathic pain states, including old agents: carbamazepine, sodium valproate, phenytoin and newer agents: gabapentin, lamotrigine, felbamate and pregabalin. Anticonvulsants have a specific indication in the treatment of trigeminal neuralgia with carbamazepine the first line therapy. They

may prove effective in conditions that have proved intractable to other treatments.

Mechanism of action

The neuronal hyperexcitability and corresponding molecular changes in neuropathic pain have many features in common with the cellular changes in certain forms of epilepsy.⁴⁸ The pain relieving effect of anticonvulsants is thought to be due to dampening of abnormal central nervous activity that follows nerve damage.⁴⁹ This may occur by:^{50,51}

- 1) Sodium channel blockade resulting in a reduction of ectopic firing in both peripheral nerves and the dorsal root ganglion
- 2) Indirect or direct enhancement of inhibitory GABAergic neurotransmission
- 3) Inhibition of excitatory glutaminergic neurotransmission

Overall effects may be due to a combination of these mechanisms and longer term neuroplastic effects.⁵¹ The process of ectopic impulse generation is so sensitive to sodium channel blockade that these agents have an action at much lower concentrations than that required to block normal neuronal transmission.⁵²

Individual medications

Clonazepam

Clonazepam is a benzodiazepine anticonvulsant acting as a GABA agonist. Lorazepam, nitrazepam and diazepam have also been used in chronic pain. They have anxiolytic and anticonvulsant properties. However, with the exception of clonazepam, benzodiazepines are not generally felt to have specific analgesic activity and their use is not encouraged for this purpose due to their addictive nature, tolerance and cognitive impairment.⁵³

However, for clonazepam several studies

suggest a role in lancinating neuropathic pain. The old cross-over trial by Swerdlow shows clonazepam to be superior to carbamazepine, phenytoin and sodium valproate with regard to efficacy in neuropathic pain and adverse effects.⁵⁴

This reflects our past clinical experience, where clonazepam was an easy to use agent with excellent efficacy and minimal side effects, in particular sedation. However, clonazepam is a benzodiazepine and thereby closely linked to risks of tolerance, dependence and addiction/abuse and should no longer be used as a first-line agent in neuropathic pain.

Gabapentin

Gabapentin is a relatively new anticonvulsant, available in the USA since 1995. It is a lipophilic GABA analogue but does not interact with GABA_A or GABA_B receptors or directly affect GABA uptake.⁵⁵ It is now clear that this drug has a modulating effect on the $\alpha 2\text{-}\delta$ subunit of voltage-gated calcium channels, an unexpected pharmacological target.⁵⁶ By modulating the calcium influx into hyperexcitable primary afferent neurons, gabapentin reduces the release of excitatory amino acids, in particular glutamate, and thereby reduces the excitation of secondary neurons. This explains its effects in neuropathic pain, but also in other conditions presenting with hyperalgesia and allodynia including fibromyalgia, even postoperative⁵⁷ and burns pain⁵⁸ and its anxiolytic effect with efficacy in generalised anxiety disorder. Large scale RCTs have demonstrated efficacy in PHN and diabetic neuropathy at target doses of 3600mg/day.⁵⁹⁻⁶¹

The Cochrane review reports NNT of 3.9 in PHN and 2.9 for painful diabetic neuropathy.⁶² Results indicate a similar efficacy of gabapentin and TCAs.⁶³

A case report cited a significant improvement with gabapentin treatment in a patient with central post stroke pain that had failed

to respond to a variety of analgesics.⁶⁴ Gabapentin was also effective in the treatment of central neuropathic pain after spinal cord injury.⁶⁵

The most commonly reported side effects are somnolence, fatigue, ataxia and dizziness. A dose adjustment is required in renal failure, but not in hepatic disorders as gabapentin is excreted unchanged by the kidneys.

The effective analgesic dose of gabapentin is variable, with some patients responding at low doses and others requiring high doses (more than 3600mg/day) for the same benefit. This is partially due to uptake by an active carrier process, showing saturation kinetics. It has been suggested that treatment failure maybe due to inadequate dosage, although rapid dose escalation can be responsible for the high incidence of CNS side effects.⁶⁶ The development of pregabalin with better kinetics and higher efficacy has reduced the usage of gabapentin.

Pregabalin

Pregabalin, an analogue to gabapentin, has been developed with an indication for neuropathic pain. It has a similar pharmacodynamic effect to gabapentin, i.e. modulates the $\alpha 2\text{-}\delta$ subunit of voltage-gated calcium channels and thereby reduces excitatory amino acid release.⁶⁶ It differs from gabapentin insofar as it has a higher potency, a better bioavailability, linear absorption kinetics and a longer half-life permitting twice instead of three times daily dosing.

Pregabalin is used successfully in a number of neuropathic pain states of peripheral and central origin including PHN, diabetic neuropathy (NNT 3.24)⁶⁷ and spinal cord injury pain.⁶⁸ It has also been used successfully in fibromyalgia⁶⁹ and generalised anxiety disorder⁷⁰ and has these three conditions as an indication in many countries. It is not only superior to gabapentin from a pharmacokinetic point of

view, but also in clinical practice achieving better pain relief and quality of life.⁷¹

Adverse effects of pregabalin include sedation, drowsiness, disturbance of balance and unexplained peripheral oedema. However, these adverse effects are often mild and can be partially avoided by slow and careful titration of the dose. Starting doses of 75mg in ambulatory patients (with 25mg in the frail), starting with an evening dose and higher evening than morning doses are useful recommendations for the titration process.

The efficacy of pregabalin and its mild adverse effects have made it a viable first-line alternative to antidepressants in the setting of neuropathic pain. An interesting aspect from a surgical perspective is its perioperative use, which leads to improved postoperative pain, reduced opioid consumption and opioid side effects.⁵⁷ Two more recent studies suggest further benefit from its perioperative use by improving recovery after laminectomy⁷² and reducing chronic neuropathic pain after knee joint replacement.⁷³

Carbamazepine

Carbamazepine has been the first line treatment for trigeminal neuralgia for many years.⁷⁴ A recent Cochrane review found that three placebo-controlled trials of carbamazepine in trigeminal neuralgia demonstrated a combined NNT of 2.5.⁷⁵ It has not however been shown to be efficacious in PHN or central pain and its use in other neuropathic states has been reported only in small uncontrolled studies. Evidence shows carbamazepine inhibits spontaneous and evoked responses of spinal neurones and increases brain serotonin. Doses of up to 1200mg/day can be used.

Side effects are the main limitation to its use and include sedation, ataxia, drug interactions and liver dysfunction.⁷⁶ Serious but rare side effects are irreversible aplastic anaemia and Stevens-Johnson-Syndrome.

With carbamazepine therapy regular haematological and liver function monitoring is required. Occasional monitoring of serum sodium is also recommended because hyponatraemia can occur. The sustained release preparations of carbamazepine may limit the side effects.

Sodium valproate

This is structurally unrelated to other anticonvulsants and does not block sodium channels. The exact mechanism of action is unknown but may be related to increased GABA synthesis and release and hence potentiated GABAergic inhibition. In addition valproate attenuates the neuronal excitation caused by glutamate activation of NMDA receptors.⁷⁷ There is evidence for its use in migraine prophylaxis⁷⁸ and some for second line therapy in trigeminal neuralgia.⁷⁹ It can be used in doses up to 800mg/day.

Again side effects and the risk of serious toxicity limit its use. These include sedation, gastrointestinal disturbance, altered liver function with potentially fatal hepatotoxicity, decreased platelet aggregation and other haematological effects and drug interactions. Close follow up is mandatory.

Phenytoin

Phenytoin can be of help in patients with neuropathic pain but less so than carbamazepine. It has fallen from favour mainly due to its extensive side effect profile, complex kinetics and drug interactions and a lack of supportive studies.

Side effects include sedation, gingival hypertrophy, hirsutism and coarsening of facial features. At high blood levels neurotoxicity occurs and cardiac conduction is affected and thus close blood drug level monitoring is required. Results from RCTs have shown an analgesic effect in diabetic neuropathy and Fabry's disease.^{80,81} The Cochrane review found that NNT for diabetic neuropathy with phenytoin was 2.1.⁷⁵

Lamotrigine

This new anticonvulsant appears to act on voltage-gated cation channels (calcium and potassium) as well as inhibiting glutamate release.⁸² Studies (open and double blind) have indicated that lamotrigine can be effective in diabetic neuropathy, central post stroke pain, HIV associated polyneuropathy and trigeminal neuralgia.^{48,53,83} It may be useful in cases of trigeminal neuralgia that have proven refractory to carbamazepine and phenytoin, in doses of 50–400mg/day.⁵³ However, other evidence suggests that it may not be more effective than placebo in many other cases of neuropathic pain.⁸²

Side effects have restricted the use of lamotrigine: dizziness, constipation, nausea, somnolence and diplopia.⁵³ Lamotrigine is associated with Steven-Johnson-Syndrome with 1:1000 patients requiring hospitalisation and can be rarely fatal. These side effects can be lessened and the incidence of rash significantly decreased by slow titration of lamotrigine, starting at a dose of 12.5 to 25 mg per day and slowly increasing to 100 to 200 mg per day over 1 to 2 months.

Recommendations for clinical use of anticonvulsants as analgesics

Anticonvulsants are typically used for neuropathic pain that has a shooting, burning or lancinating character. Empirically they are often used in combination with a TCA, although the evidence for using both classes of drug in combination is not strong.

For peripheral neuropathic pain and spinal cord injury pain pregabalin is the anticonvulsant of choice.² For trigeminal neuralgia only, carbamazepine is the first choice.² Although few trials exist for the treatment of central post-stroke pain, current opinion is that lamotrigine and gabapentin may be helpful.⁸⁴

As with antidepressants, titration should start with low doses, gradually increasing to

a dose that either produces analgesic efficacy or unacceptable side effects.

Local anaesthetics and antiarrhythmics

In 1948 systemic procaine was identified as beneficial in the treatment of neuropathic pain. This led to the evaluation of other local anaesthetics for the treatment of neuropathic pain.

Mechanism of action

The mechanism of analgesic action is thought to be due to membrane stabilising effects by blockade of voltage-dependent sodium channels and hence reduced ectopic activity in damaged afferent nerves.⁵⁰ In addition there maybe a central action on sodium channels and at the spinal level, blocking the actions of glutamate.^{85,86}

Lignocaine

Over the last 35 years there have been reports of analgesic efficacy of intravenous lignocaine in a wide range of neuropathic pain states, including diabetic neuropathy, peripheral nerve lesions, PHN and central pain.⁸⁷⁻⁹² Sakuri and Kanazawa have reported its effectiveness in multiple sclerosis associated pain.⁹³ There is large variation in reported duration of analgesic effect, varying from no residual effect to 20 weeks benefit in patients with central pain. A beneficial response to a lignocaine infusion may suggest a similar benefit from oral mexiletine, but does not predict this reliably.⁹⁴

Mexiletine

This antiarrhythmic is an oral analogue of lignocaine that has been used in neuropathic pain with mixed results. Some effectiveness has been demonstrated in treating pain after peripheral nerve injuries and painful diabetic neuropathy, although these findings are not

consistent and the effects are less than that provided by TCAs and anticonvulsants with an NNT of 10.⁹⁵ Optimal dosing may be a problem with a poor therapeutic ratio and potential cardiotoxicity.⁴ Mexiletine should only be regarded as a last resort in the treatment of neuropathic pain.

Recommendations for clinical use of lignocaine and mexilitine in neuropathic pain

Side effects of both substances are CNS (dizziness, nausea, perioral numbness, convulsions & coma) and CVS effects (arrhythmias). Contraindications therefore include, cardiac conduction abnormalities, left ventricular failure and ischaemic heart disease. An ECG should be obtained before and during treatment to monitor any cardiac effects. If there is a question regarding safety in a patient, a cardiologist's opinion should be sought, prior to starting treatment.

For lignocaine the recommended starting dose is 1–1.5mg/kg as a slow IV bolus; this is an ideal agent for the neuropathic pain emergency. Maintenance is by IV infusion of 1-3mg/min with measurement of blood concentrations. The recommended starting dose for mexiletine is 150mg three times a day with a slow increase to 600mg to 1200mg per day to optimal results.

N-methyl-D-aspartate-receptor (NMDA) antagonists

NMDA receptors are activated by the excitatory neurotransmitter glutamate. NMDA antagonists are thought to play an important role in the development of central sensitisation following a peripheral nerve lesion. They may block this hyperactivity responsible for the maintenance of the pain. Drugs with NMDA receptor antagonist activity include ketamine, dextromethorphan, memantine and amantadine.

Ketamine

Ketamine is the most commonly used NMDA antagonist. Its original use was as an anaesthetic agent, particularly 'in the field' and other difficult locations and situations. It has also been used for the treatment of severe asthma and for sedation. However, ketamine is known to have analgesic properties at subanaesthetic doses.⁹⁶

Analgesic efficacy of ketamine has been demonstrated in RCTs for PHN, peripheral nerve injuries, phantom limb pain and post stroke central pain.⁹⁶ In peripheral⁹⁷ and central neuropathic pain states,⁹⁸ low-dose IV ketamine was superior to IV lignocaine. Ketamine may in part provide analgesia by reversing opioid tolerance.⁹⁹ In opioid-tolerant patients low-dose ketamine improves postoperative analgesia and reduces opioid requirements.

Unpleasant side effects limit its use, although they occur rarely with the low doses commonly used to treat neuropathic pain. These are mostly psychomimetic: sedation, hallucinations, dysphoria, unpleasant sensations (dissociation) and paranoid feelings. It is important to warn patients in advance of these potential effects; they can be reduced by co-prescribing benzodiazepines such as midazolam if needed. The pharmacokinetics of a sublingual and oral dosing form have been documented¹⁰⁰ and a nasal spray of ketamine is under development.¹⁰¹

Other NMDA antagonists

Dextromethorphan, amantidine and memantine have been shown to have weaker actions than ketamine. In a blinded trial, Nelson *et al* demonstrated an analgesic effect with high dose dextromethorphan in painful diabetic neuropathy,¹⁰² but this has not been reproduced in other neuropathic pain states.¹⁰³ Memantine was also shown to be ineffective in phantom limb pain treatment;¹⁰⁴ its routine use in neuropathic pain can currently not be recommended.¹⁰⁵

Miscellaneous compounds for systemic use

Clonidine

Clonidine is an α_2 -agonist with analgesic activity. Its analgesic action is thought to occur centrally and at a spinal level, mediated by activation of α_2 -adrenoceptors in the dorsal horn of the spinal cord. This results in direct inhibition of postsynaptic spinal dorsal horn neurones or by decreasing the release of noradrenaline from sympathetic nerve terminals.

Efficacy

Only a small number of studies have been conducted to look at a potential role in the treatment of neuropathic pain. Significant improvement was reported in patients with PHN treated with clonidine.¹⁰⁶ Transdermal clonidine (0.1 to 0.3mg per day) has been used with success in patients with diabetic neuropathies.^{107,108} A double blind crossover study in 20 chronic pain patients, comparing epidural clonidine and an epidural combination of morphine and lignocaine found epidural clonidine to be as effective as epidural morphine in 20 chronic pain patients.¹⁰⁹ It is registered in the USA as an adjuvant in combination with epidural local anaesthetics and opioids for resistant neuropathic pain. Side effects include drowsiness, dizziness and dry mouth.

Baclofen

Baclofen is a gamma-aminobutyric acid (GABA) receptor agonist, capable of crossing the blood-brain barrier. It is an agonist at GABA-B receptors and has presynaptic action in the spinal cord preventing the release of excitatory neurotransmitters.¹¹⁰

Baclofen causes muscle relaxation and is used to treat muscle spasticity. It has been shown to have antinociceptive action and has been used to treat neuropathic pain.¹¹¹ It was

first used for this purpose to treat trigeminal neuralgia.¹¹² Its efficacy has not however been confirmed in other neuropathic pain conditions.¹¹³ Baclofen has been administered intrathecally and may be useful for pain related to spinal cord injuries.¹¹⁴ Side effects include sedation, nausea, confusion, convulsions, hypotension, GI upset, visual disturbances and occasionally hepatic impairment (A to Z). After prolonged use, baclofen requires a gradual dose reduction in order to minimise the risk of a withdrawal syndrome.¹¹⁰

Levodopa

Ertas *et al* found levodopa to be better than placebo in treating painful diabetic neuropathy.¹¹⁵ A review of placebo-controlled trials by Sindrup and Jensen in patients with diabetic neuropathy showed that NNT was 3.4 for levodopa, compared with 6.7 for SSRIs.⁹⁵ A placebo-controlled trial has demonstrated efficacy in acute herpes zoster pain.¹¹⁶

Cannabinoids

There has been increasing interest in the use of cannabis and cannabinoids as analgesics in chronic pain. Cannabinoid receptors are located in the central and peripheral nervous system. Animal models have shown that cannabinoid receptors do not undergo down-regulation after nerve lesions (unlike opioid receptors) and that cannabinoids may attenuate the associated sensory changes.⁸

Cannabis has been used for thousands of years for medicinal and recreational purposes. There is much interest surrounding its legalisation and its potential role as an analgesic. The data situation here remains unclear; however, overall there is a trend to show some efficacy by some cannabinoids in some neuropathic pain states. A meta-analysis found efficacy in neuropathic pain states

including multiple sclerosis.¹¹⁷ Similarly, a randomised trial of smoked cannabis in neuropathic pain reduced pain intensity and improved sleep quality.¹¹⁸ However, a trial in spinal cord injury pain failed to show efficacy.¹¹⁹ Adverse effects associated with cannabinoids are common, the main being sedation, disorientation, ataxia, memory impairment, dry mouth and blurred vision.

Larger blinded, randomised controlled trials are required before it can be ascertained whether cannabinoids are efficacious in neuropathic pain. The development of new safe and effective agonists that separates the psychotropic effects from the therapeutic ones would improve trial designs.

Topical treatments

Allodynia is frequently a feature of neuropathic pain especially in PHN, traumatic neuropathies and causalgia. It may therefore be helpful to consider the use of topical medications for the treatment of cutaneous hyperalgesia in these cases. There are a few options in the form of capsaicin, local anaesthetics (and NSAIDs with some reports of good pain relief from post herpetic neuralgia with topical aspirin preparations).¹²⁰⁻¹²²

Lignocaine 5% medicated plaster

In patients with PHN, success has been reported using lignocaine patches or topically applied gel to painful areas.^{52,123,124} The mechanism of action is thought to involve suppression of ectopic discharges from sensory afferents and from providing mechanical protection to underlying allodynic skin.¹²⁵ In 1999 the FDA approved the use of 5% topical lignocaine patches for treatment of PHN. It is recommended as a first-line approach for this indication and other localised neuropathic pain states.¹²⁶ A meta-analysis showed superiority of the plaster over capsaicin and pregabalin and

similar efficacy to gabapentin, however with significantly fewer systemic side effects.¹²⁷

The advantages of this route of administration are its effectiveness, duration of analgesia, ease of application without dose titration and lack of systemic side effects. The safety profile is particularly advantageous in the elderly population whom are most affected by PHN. The area of pain has however to be of limited size for practical application.

Capsaicin

Capsaicin is the pungent component to chilli peppers. The chilli pepper has been recognised by various cultures for many years for its medicinal qualities.¹²⁸ It is neurotoxic and has analgesic properties. When capsaicin is applied topically it initially causes a burning sensation and heat hyperalgesia that decreases with subsequent applications.

Mechanism of Action

Capsaicin acts on receptors at the terminals of primary nociceptive afferents. In 1997 a specific receptor on C fibres was cloned, a vanilloid receptor, the VR-1 receptor. When capsaicin binds to this receptor, it induces initial activation of the nociceptors, hence the burning sensation. It depletes substance P from the sensory nerve terminals of peripheral nociceptors. With repeat or prolonged application, this is followed by desensitisation and inactivation of the receptive terminals of the nociceptors.¹²⁹ There is also evidence that it causes depletion of substance P in epidermal nerve fibres.¹³⁰

Efficacy

In a meta-analysis of RCTs, low-dose capsaicin cream (0.075%) repeatedly administered had an NNT of 6.6 for any pain relief.¹³¹ A commercially available patch with high-dose capsaicin (8%) had an NNT of 12 for 30% pain relief. These not very impressive results

have to be seen in the context of a potentially high placebo effect, as the burning feeling after administration results in the patient effectively being unblinded. This criticism is confirmed by one double blind trial using a placebo with a similar burning sensation and finding no difference in analgesic efficacy between placebo and capsaicin.¹³²

The use of capsaicin has been limited by this unpleasant burning sensation occurring in 60–70% patients, need for frequent applications and uncertain efficacy.⁴ Co-administration of lignocaine gel has been used in order to improve compliance.⁴

Capsaicin can only be seen as an adjuvant treatment and second line therapy.

NON PHARMACOLOGICAL THERAPY

Transcutaneous electrical nerve stimulation (TENS)

This technique applies cutaneous electrodes to stimulate peripheral nerves to relieve pain.¹³³ This is based on the gate control theory of pain transmission, so that by stimulating A β and A δ fibres pain transmission by C-fibres is inhibited. It utilises a pulse generator that provides a range of currents, frequencies and pulse widths. The surface electrodes are placed on either side of the painful area or alternatively over the nerves supplying that area. The current is then increased until a tingling sensation is felt in the painful area, the timing and duration of pulses is a matter of titration to maximal response. TENS may reduce analgesic requirements.¹³⁴ A meta-analysis shows improvement in neuropathic symptoms in patients with diabetic polyneuropathy.¹³⁵

It has few side effects and complications, allergic dermatitis may occur at the contact sites and its use is contraindicated in patients with pacemakers. Its efficacy can be assessed

quickly (there is a significant placebo effect) and can therefore be easily trialled for any potential benefit to an individual.¹³⁶ Unfortunately tolerance may develop resulting in loss of previously effective analgesia, changing the stimulation variables can sometimes attenuate this.

Spinal cord stimulation (SCS)

This technique requires an implantable device with electrodes positioned under direct vision at open laminectomy or via a needle in the epidural space percutaneously. The electrodes are placed above the level of the pain and connected to an inductance coil placed on the abdominal wall; an implantable power source can also be used. The mechanism of action is not yet clear, but it seems to be not effective in nociceptive pain, but only in neuropathic pain.¹³⁷ It seems that this device can be as useful for a variety of neuropathic and chronic pain states.¹³⁸ A systematic review describes efficacy in refractory neuropathic back and leg pain, failed back surgery syndrome and chronic regional pain syndrome (CRPS) Type 1.¹³⁹

Complications include infection, bleeding, dural puncture and hardware failure; decisions on use of this invasive and expensive approach should be made ideally by a multidisciplinary team experienced in the use of such techniques. Deep brain stimulation and motor cortex stimulation have also been used to treat neuropathic pain.¹⁴⁰

Sympathetic nerve blocks

The diagnosis of sympathetically maintained pain can be confirmed by the response to a sympatholytic procedure. This may be helpful, if there is a significant sympathetic component to the patient's pain. A patient should receive sustained pain relief after

administration of a sympathetic chain or sympathetic plexus local anaesthetic block or accumulative relief from a number of procedures. If the patient fails to respond, a systematic pharmacological approach is tried. However, a block may be incorrectly thought to be successful. This can happen for one of two reasons: either, the local anaesthetic is absorbed and provides a systemic analgesic effect or it diffuses locally and acts on nearby somatic nerves.¹⁴¹

In case of effectiveness, progression to a sympatholytic procedure can be chosen. Techniques then involve the use of neurolytic substances or radiofrequency ablation; regrettably the current scientific basis for this approach is poor.¹⁴²

Neurosurgical destructive techniques

There has been increasing awareness that destructive techniques may in fact increase pain in the long term due to the plasticity of the nervous system, sometimes resulting in incapacitating side effects. Therefore these techniques, which include neurectomy and dorsal root entry zone lesions, are now rarely used.¹⁴³ The exception being in the treatment of trigeminal neuralgia, which has proved refractory to pharmacological treatments. In this situation a variety of surgical procedures can provide rapid pain relief, the most effective option being microvascular decompression. Recurrence is still a risk but appears to be more frequent after percutaneous radiofrequency rhizotomy or compression with a percutaneously positioned balloon than the more invasive microvascular decompression technique.¹⁴⁴

Cognitive-behavioural therapy

Chronic neuropathic pain is best managed in a multidisciplinary pain clinic.¹⁴⁵ This is because the patient often has cognitive,

affective and behavioural factors influencing their pain; however new understandings of the physiology of cortical reorganisation in chronic pain might also lead to new psychological approaches.¹⁴⁶ A multi-disciplinary approach will address both the somatic and psychological aspects of the patient's condition. The main methods are cognitive-behavioural therapy and operant conditioning.

The cognitive-behavioural approach aims to identify and modify the patient's thoughts, feelings, beliefs and behaviour. Common problems are anxiety, depression and the development of fear-avoidance. Behavioural therapy procedures are utilised to bring about change. The aims are to enable patients to take a positive and active role in coping with their pain and to change maladaptive behaviour that may be aggravating the problem.

Operant conditioning uses firstly continuous re-enforcement to encourage positive behaviour from the patient that is then stepped down later on. This is based on the belief that the consequence of certain behaviour determines whether it is likely to recur.

Psychotherapy may increase levels of activity and decrease medication requirements but an actual reporting in pain reduction may be more modest. In addition the therapy may need to be extended to the carers of the patient in order to change their response to the patient's beliefs and behaviour. The current data situation on this approach to neuropathic pain is insufficient to draw any conclusions on efficacy.¹⁴⁷

REFERENCES

1. Merskey H, Bogduk N, editors. *Classification of Chronic Pain* 2nd ed. Seattle: IASP Press; 1994.
2. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *Eur J Neurol* 2010; **17**: 1113–e88.
3. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. *Pain* 2007; **132**: 237–51.
4. Attal N. Chronic neuropathic pain: mechanisms and treatment. *Clin J Pain* 2000; **16**: S118–30.
5. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. *Pain* 1988; **33**: 11–23.
6. Besse D, Lombard MC, Besson JM. Autoradiographic distribution of mu, delta and kappa opioid binding sites in the superficial dorsal horn, over the rostrocaudal axis of the rat spinal cord. *Brain Res* 1991; **548**: 287–91.
7. DelleMijn PL, Vanneste JA. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. *Lancet* 1997; **349**: 753–8.
8. Bridges D, Thompson SW, Rice AS. Mechanisms of neuropathic pain. *Br J Anaesth* 2001; **87**: 12–26.
9. Rohde DS, Detweiler DJ, Basbaum AI. Spinal cord mechanisms of opioid tolerance and dependence: Fos-like immunoreactivity increases in subpopulations of spinal cord neurons during withdrawal [corrected]. *Neuroscience* 1996; **72**: 233–42.
10. Benedetti F, Vighetti S, Amanzio M, et al. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. *Pain* 1998; **74**: 205–11.
11. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. *Cochrane Database Syst Rev* 2006; **3**: CD006146.

12. Przewlocki R, Przewlocka B. Opioids in neuropathic pain. *Curr Pharm Des* 2005; **11**: 3013–25.
13. Stein C, Reinecke H, Sorgatz H. Opioid use in chronic noncancer pain: guidelines revisited. *Curr Opin Anaesthesiol* 2010; **23**: 598–601.
14. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain* 2009; **10**: 113–30.
15. Hall W, Degenhardt L. Regulating opioid prescribing to provide access to effective treatment while minimizing diversion: an overdue topic for research. *Addiction* 2007; **102**: 1685–8.
16. Mannino R, Coyne P, Swainey C, et al. Methadone for cancer-related neuropathic pain: a review of the literature. *Journal of opioid management* 2006; **2**: 269–76.
17. Moulin DE, Palma D, Watling C, Schulz V. Methadone in the management of intractable neuropathic noncancer pain. *Can J Neurol Sci* 2005; **32**: 340–3.
18. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. *Journal of Pharmacology & Experimental Therapeutics* 1992; **260**: 275–85.
19. Raffa RB, Friderichs E. The basic science aspect of tramadol hydrochloride. *Pain Rev* 1996; **3**: 249–271.
20. Driessen B, Reimann W. Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. *Br J Pharmacol* 1992; **105**: 147–51.
21. Driessen B, Reimann W, Giertz H. Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. *British Journal of Pharmacology* 1993; **108**: 806–811.
22. Christoph T, Kogel B, Strassburger W, Schug SA. Tramadol has a better potency ratio relative to morphine in neuropathic than in nociceptive pain models. *Drugs R D* 2007; **8**: 51–7.
23. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. *Neurology* 1998; **50**: 1842–1846.
24. Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. *Pain* 1999; **83**: 85–90.
25. Hollingshead J, Duhmke RM, Cornblath DR. Tramadol for neuropathic pain. *Cochrane Database Syst Rev* 2006; **3**: CD003726.
26. Langford RM, Bakhshi KN, Moylan S, Foster MG. Hypoxaemia after lower abdominal surgery: Comparison of tramadol and morphine. *Acute Pain* 1998; **1**: 7–12.
27. Wilder-Smith CH, Hill L, Osler W, O'Keefe S. Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. *Digestive Diseases & Sciences* 1999; **44**: 1107–1116.
28. Senay EC, Adams EH, Geller A, et al. Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. *Drug Alcohol Depend* 2003; **69**: 233–41.
29. Cicero TJ, Adams EH, Geller A, et al. A postmarketing surveillance program to monitor Ultram (tramadol

- hydrochloride) abuse in the United States. *Drug Alcohol Depend* 1999; **57**: 7–22.
30. Preston KLJ-C, 2006 #9827}, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. *Drug & Alcohol Dependence* 1991; **27**: 7–17.
 31. Cicero TJ, Inciardi JA, Adams EH, et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994–2004. *Pharmacoepidemiol Drug Saf* 2005; **14**: 851–9.
 32. Cossmann M, Kohnen C. General tolerability and adverse event profile of tramadol. *Revisions of Contemporary Pharmacotherapy* 1995; **6**: 513–531.
 33. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. *Pain* 1992; **49**: 205–19.
 34. Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. *Pain* 1992; **48**: 29–36.
 35. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane Database Syst Rev* 2007: CD005454.
 36. Max MB. Antidepressants as analgesics. In: Fields HL, Liebeskind JC, editors. *Progress in pain research and therapy*. Seattle: IASP Press; 1994. 229–246.
 37. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. *Clin Pharmacol Ther* 1990; **47**: 305–12.
 38. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. *Neurology* 1987; **37**: 589–96.
 39. Gray AM, Spencer PS, Sewell RD. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. *Br J Pharmacol* 1998; **124**: 669–74.
 40. McQuay HJ, Tramer M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. *Pain* 1996; **68**: 217–27.
 41. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. *N Engl J Med* 1992; **326**: 1250–6.
 42. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. *Harv Rev Psychiatry* 2000; **7**: 257–77.
 43. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. *Cochrane Database Syst Rev* 2009: CD007115.
 44. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. *BMC Neurology* 2008; **8**: 29.
 45. Sindrup SH, Grodum E, Gram LF, Beck-Nielsen H. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study. *Ther Drug Monit* 1991; **13**: 408–14.
 46. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. *Anaesthesia* 1993; **48**: 281–5.
 47. Ellenberg M. Treatment of diabetic neuropathy with diphenylhydantoin. *NY State J Med* 1968; **68**: 2653–5.
 48. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical

- evidence. *Eur J Pain* 2002; **6** Suppl A: 61–8.
49. Tasker RR, Tsuda T, Hawrylyshyn P. Clinical neurophysiological investigation of deafferentation pain. In: Bonica JJ, editor. *Advances in pain research and therapy*. New York: Raven Press; 1983. 713–738.
 50. Tanelian DL, Brose WG. Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine. *Anesthesiology* 1991; **74**: 949–51.
 51. Soderpalm B. Anticonvulsants: aspects of their mechanisms of action. *Eur J Pain* 2002; **6** Suppl A: 3–9.
 52. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. *Ann Neurol* 1995; **37**: 246–53.
 53. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. *Neurology* 2002; **59**: S14–7.
 54. Swerdlow M, Cundill JG. Anticonvulsant drugs used in the treatment of lancinating pain. A comparison. *Anaesthesia* 1981; **36** No 12: 1129–1132.
 55. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. *Neurology* 1994; **44**: S10–6.
 56. Thorpe AJ, Offord J. The alpha2–delta protein: An auxiliary subunit of voltage-dependent calcium channels as a recognized drug target. *Curr Opin Investig Drugs* 2010; **11**: 761–70.
 57. Tiippana EM, Hamunen K, Kontinen VK, Kalso E. Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. *Anesth Analg* 2007; **104**: 1545–56, table of contents.
 58. Gray P, Williams B, Cramond T. Successful use of gabapentin in Acute Pain management following burn injury: a case series. *Pain Med* 2008; **9**: 371–6.
 59. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial [see comments]. *Jama* 1998; **280**: 1831–6.
 60. Backonja MM. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. *Epilepsia* 1999; **40** Suppl 6: S57–9.
 61. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. *Jama* 1998; **280**: 1837–42.
 62. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. *Cochrane Database Syst Rev* 2005: CD005452.
 63. Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. *Arch Intern Med* 1999; **159**: 1931–7.
 64. Chen B, Stitik TP, Foye PM, et al. Central post-stroke pain syndrome: yet another use for gabapentin? *Am J Phys Med Rehabil* 2002; **81**: 718–20.
 65. Tai Q, Kirshblum S, Chen B, et al. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. *The journal of spinal cord medicine* 2002; **25**: 100–5.


66. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. *Clin J Pain* 2001; **17**: 284–95.
67. Hurley RW, Lesley MR, Adams MC, et al. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. *Reg Anesth Pain Med* 2008; **33**: 389–94.
68. Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. *Neurology* 2006; **67**: 1792–800.
69. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. *J Rheumatol* 2008; **35**: 502–14.
70. Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. *Cns Drugs* 2006; **20**: 685–93; discussion 694–5.
71. Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. *Pain Med* 2010; **11**: 456–65.
72. Burke SM, Shorten GD. Perioperative pregabalin improves pain and functional outcomes 3 months after lumbar discectomy. *Anesth Analg* 2010; **110**: 1180–5.
73. Buvanendran A, Kroin JS, Della Valle CJ, et al. Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial. *Anesth Analg* 2010; **110**: 199–207.
74. Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbamazepine (tegretol) in trigeminal neuralgia. *J Neurol Neurosurg Psychiatry* 1966; **29**: 265–7.
75. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. *Cochrane Database Syst Rev* 2000: CD001133.
76. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use and side effects. *Arch Neurol* 1968; **19**: 129–36.
77. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. *Prog Neurobiol* 1999; **58**: 31–59.
78. Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. *Headache* 1996; **36**: 547–55.
79. Peiris JB, Perera GL, Devendra SV, Lionel ND. Sodium valproate in trigeminal neuralgia. *Med J Aust* 1980; **2**: 278.
80. Chadda VS, Mathur MS. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. *J Assoc Physicians India* 1978; **26**: 403–6.
81. Lockman LA, Hunninghake DB, Krivit W, Desnick RJ. Relief of pain of Fabry's disease by diphenylhydantoin. *Neurology* 1973; **23**: 871–5.
82. McClean G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. *Pain* 1999; **83**: 105–7.
83. Eisenberg E, Alon N, Ishay A, et al. Lamotrigine in the treatment of painful diabetic neuropathy. *Eur J Neurol* 1998; **5**: 167–173.
84. Kim JS. Post-stroke pain. *Expert Rev Neurother* 2009; **9**: 711–21.
85. Biella G, Sotgiu ML. Central effects of systemic lidocaine mediated by glycine spinal receptors: an iontophoretic study in the rat spinal cord. *Brain Res* 1993; **603**: 201–6.

86. Woolf CJ, Wiesenfeld-Hallin Z. The systemic administration of local anaesthetics produces a selective depression of C-afferent fibre evoked activity in the spinal cord. *Pain* 1985; **23**: 361–74.
87. Boas RA, Covino BG, Shahnarian A. Analgesic responses to i.v. lignocaine. *Br J Anaesth* 1982; **54**: 501–5.
88. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. *Neurology* 1991; **41**: 1024–1028.
89. Marchettini P, Lacerenza M, Marangoni C, et al. Lidocaine test in neuralgia. *Pain* 1992; **48**: 377–82.
90. Wallace MS, Dyck JB, Rossi SS, Yaksh TL. Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury. *Pain* 1996; **66**: 69–77.
91. Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. *J Pain Symptom Manage* 1999; **17**: 429–33.
92. Attal N, Gaude V, Brasseur L, et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. *Neurology* 2000; **54**: 564–74.
93. Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. *J Neurol Sci* 1999; **162**: 162–8.
94. Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. *J Pain Symptom Manage* 1996; **12**: 161–7.
95. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. *Pain* 1999; **83**: 389–400.
96. Visser E, Schug SA. The role of ketamine in pain management. *Biomed Pharmacother* 2006; **60**: 341–8.
97. Kvarnstrom A, Karlsten R, Quiding H, et al. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. *Acta Anaesthesiol Scand* 2003; **47**: 868–77.
98. Kvarnstrom A, Karlsten R, Quiding H, Gordh T. The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. *Acta Anaesthesiol Scand* 2004; **48**: 498–506.
99. Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. *Clin J Pain* 2000; **16**: S73–9.
100. Chong C, Schug SA, Page-Sharp M, et al. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study. *Clin Drug Investig* 2009; **29**: 317–24.
101. Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. *Pain* 2004; **108**: 17–27.
102. Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. *Neurology* 1997; **48**: 1212–8.
103. McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled

- crossover trial with integral n-of-1 design. *Pain* 1994; **59**: 127–33.
104. Maier C, Dertwinkel R, Mansourian N, et al. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain - results of a randomized double-blinded, placebo-controlled trial. *Pain* 2003; **103**: 277–83.
 105. Rogers M, Rasheed A, Moradimehr A, Baumrucker SJ. Memantine (Namenda) for neuropathic pain. *Am J Hosp Palliat Care* 2009; **26**: 57–9.
 106. Max MB, Schafer SC, Culnane M, et al. Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. *Clin Pharmacol Ther* 1988; **43**: 363–71.
 107. Zeigler D, Lynch SA, Muir J, et al. Transdermal clonidine versus placebo in painful diabetic neuropathy. *Pain* 1992; **48**: 403–8.
 108. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. *Pain* 1995; **60**: 267–74.
 109. Glynn C, Dawson D, Sanders R. A double-blind comparison between epidural morphine and epidural clonidine in patients with chronic non-cancer pain. *Pain* 1988; **34**: 123–128.
 110. Fromm GH. Baclofen as an adjuvant analgesic. *J Pain Symptom Manage* 1994; **9**: 500–9.
 111. Hering-Hanit R. Baclofen for prevention of migraine. *Cephalalgia* 1999; **19**: 589–91.
 112. Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. *Ann Neurol* 1984; **15**: 240–4.
 113. Terrence CF, Fromm GH, Tenicela R. Baclofen as an analgesic in chronic peripheral nerve disease. *Eur Neurol* 1985; **24**: 380–5.
 114. Herman RM, D'Luzansky SC, Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. *Clin J Pain* 1992; **8**: 338–45.
 115. Ertas M, Sagduyu A, Arac N, et al. Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. *Pain* 1998; **75**: 257–9.
 116. Kernbaum S, Hauchecorne J. Administration of levodopa for relief of herpes zoster pain. *Jama* 1981; **246**: 132–4.
 117. Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. *Curr Med Res Opin* 2007; **23**: 17–24.
 118. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ* 2010; **182**: E694–701.
 119. Rintala DH, Fiess RN, Tan G, et al. Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. *Am J Phys Med Rehabil* 2010; **89**: 840–8.
 120. King RB. Concerning the management of pain associated with herpes zoster and of postherpetic neuralgia. *Pain* 1988; **33**: 73–78.
 121. De Benedittis G, Besana F, Lorenzetti A. A new topical treatment for acute herpetic neuralgia and postherpetic neuralgia: the aspirin/diethyl ether mixture. An open-label study plus a double-blind controlled clinical trial. *Pain* 1992; **48**: 383–90.

122. De Benedittis G, Lorenzetti A. Topical aspirin/diethyl ether mixture versus indomethacin and diclofenac/diethyl ether mixtures for acute herpetic neuralgia and postherpetic neuralgia: a double-blind crossover placebo-controlled study. *Pain* 1996; **65**: 45–51.
123. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for postherpetic neuralgia. *Pain* 1996; **65**: 39–44.
124. Galer BS. Advances in the treatment of postherpetic neuralgia: The topical lidocaine patch. *Today's Ther Trends* 2000; **18**: 1–20.
125. Argoff CE. Lidocaine patch 5% and the management of chronic pain. *South Med J* 2002; **95**: 781.
126. Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia. *Drugs* 2009; **69**: 2149–65.
127. Wolff RF, Bala MM, Westwood M, et al. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. *Swiss Med Wkly* 2010; **140**: 297–306.
128. Robbins W. Clinical applications of capsaicinoids. *Clin J Pain* 2000; **16**: S86–9.
129. Bjerring P, Arendt-Nielsen L, Soderberg U. Argon laser induced cutaneous sensory and pain thresholds in post-herpetic neuralgia. Quantitative modulation by topical capsaicin. *Acta Derm Venereol* 1990; **70**: 121–5.
130. Lynn B. Capsaicin: actions on nociceptive C-fibres and therapeutic potential. *Pain* 1990; **41**: 61–9.
131. Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic pain in adults. *Cochrane Database Syst Rev* 2009: CD007393.
132. Low PA, Opfer-Gehrking TL, Dyck PJ, et al. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. *Pain* 1995; **62**: 163–8.
133. Tulgar M. Advances in electrical nerve stimulation techniques to manage chronic pain: an overview. *Adv Ther* 1992; **9**: 366–72.
134. Hamza MA, White PF, Craig WF, et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. *Diabetes Care* 2000; **23**: 365–70.
135. Jin DM, Xu Y, Geng DF, Yan TB. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract* 2010; **89**: 10–5.
136. Kumar K, Toth C, Nath RK, Laing P. Epidural spinal cord stimulation for treatment of chronic pain – some predictors of success. A 15-year experience. *Surg Neurol* 1998; **50**: 110–20.
137. Meyerson BA, Linderroth B. Mechanisms of spinal cord stimulation in neuropathic pain. *Neurol Res* 2000; **22**: 285–92.
138. Kim SH, Tasker RR, Oh MY. Spinal cord stimulation for nonspecific limb pain versus neuropathic pain and spontaneous versus evoked pain. *Neurosurgery* 2001; **48**: 1056–64.
139. Taylor RS. Spinal cord stimulation in complex regional pain syndrome and refractory neuropathic back and leg

- pain/failed back surgery syndrome: results of a systematic review and meta-analysis. *J Pain Symptom Manage* 2006; **31**: S13–9.
140. Stadler JA, 3rd, Ellens DJ, Rosenow JM. Deep brain stimulation and motor cortical stimulation for neuropathic pain. *Curr Pain Headache Rep* 2011; **15**: 8–13.
141. DelleMijn PL, Fields HL, Allen RR, et al. The interpretation of pain relief and sensory changes following sympathetic blockade. *Brain* 1994; **117** (Pt 6): 1475–87.
142. Day M. Sympathetic blocks: the evidence. *Pain Pract* 2008; **8**: 98–109.
143. Sindou M, Mertens P. Neurosurgical management of neuropathic pain. *Stereotact Funct Neurosurg* 2000; **75**: 76–80.
144. Fields HL. Treatment of trigeminal neuralgia. *N Engl J Med* 1996; **334**: 1125–6.
145. Goucke CR. The management of persistent pain. *Med J Aust* 2003; **178**: 444–7.
146. Flor H. Cortical reorganisation and chronic pain: implications for rehabilitation. *J Rehabil Med* 2003; 66–72.
147. Wetering EJ, Lemmens KM, Nieboer AP, Huijsman R. Cognitive and behavioral interventions for the management of chronic neuropathic pain in adults--a systematic review. *Eur J Pain* 2010; **14**: 670–81.



Cover diagram by David Heinrich of the *Medical Illustration and Media Unit, Flinders Medical Centre*. (See chapter 18)

MECHANISMS OF VASCULAR DISEASE

Edited by Robert Fitridge and Matthew Thompson

Chapter 1: Endothelium **Chapter 2:** Vascular smooth muscle structure and function **Chapter 3:** Atherosclerosis **Chapter 4:** Mechanisms of plaque rupture **Chapter 5:** Current and emerging therapies in atheroprotection **Chapter 6:** Molecular approaches to revascularisation in peripheral vascular disease **Chapter 7:** Biology of restenosis and targets for intervention **Chapter 8:** Vascular arterial haemodynamics **Chapter 9:** Physiological haemostasis **Chapter 10:** Hypercoagulable states **Chapter 11:** Platelets in the pathogenesis of vascular disease and their role as a therapeutic target **Chapter 12:** Pathogenesis of aortic aneurysms **Chapter 13:** Pharmacological treatment of aneurysms **Chapter 14:** Aortic dissection and connective tissue disorders **Chapter 15:** Biomarkers in vascular disease **Chapter 16:** Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon **Chapter 17:** SIRS, sepsis and multiorgan failure **Chapter 18:** Pathophysiology of reperfusion injury **Chapter 19:** Compartment syndrome **Chapter 20:** Pathophysiology of pain **Chapter 21:** Postamputation pain **Chapter 22:** Treatment of neuropathic pain **Chapter 23:** Principles of wound healing **Chapter 24:** Pathophysiology and principles of varicose veins **Chapter 25:** Chronic venous insufficiency and leg ulceration: Principles and vascular biology **Chapter 26:** Pathophysiology and principles of management of the diabetic foot **Chapter 27:** Lymphoedema – Principles, genetics and pathophysiology **Chapter 28:** Graft materials past and future **Chapter 29:** Pathophysiology of vascular graft infections



BARR SMITH PRESS

An imprint of
The University of Adelaide Press